ALLODERM-Registered Trademark- CO-PROMOTION AGREEMENT
THIS ALLODERM CO-PROMOTION AGREEMENT (the "Agreement") is made and
entered into this 9th day of February, 2000 (the "Effective Date"), by and
between Obagi Medical Products, Inc. ("OMP"), a California corporation, and
LifeCell Corporation. ("LifeCell"), a Delaware corporation. OMP and LifeCell are
collectively referred to as the "Parties."
RECITALS
WHEREAS, LifeCell is a bioengineering company engaged in the
development and commercialization of tissue regeneration and cell preservation
products and holds all right, title and interest in and to AlloDerm acellular
dermal graft ("AlloDerm-Registered Trademark-");
WHEREAS, AlloDerm is prepared in two forms: prepackaged for injection
in several sizes of syringes ("Micronized AlloDerm-TM-"), and prepackaged in
several sizes in sheet form, and this Agreement relates only to Micronized
AlloDerm-TM-;
WHEREAS, OMP desires to secure exclusive rights from LifeCell for a
specific term for the co-promotion of the Products in specified markets in
identified geographic regions pursuant to the terms and conditions herein
provided; and
WHEREAS, LifeCell desires to provide exclusive rights to OMP for a
specific term for the co-promotion of the Products (as defined in Section 1) in
specified markets in identified geographic regions pursuant to the terms and
conditions herein provided;
NOW, THEREFORE, in consideration of the mutual covenants and promises
recited below, the parties, intending to be legally bound, agree as follows:
TERMS AND CONDITIONS
I. DEFINITIONS
As used in this Agreement, the following capitalized terms shall have
the following respective meanings:
"AFFILIATE" shall mean (a) any company owned or controlled to the
extent of at least fifty percent (50%) of its issued and voting capital
securities by a party to this Agreement and any other company so owned or
controlled (directly or indirectly) by any such company or the owner of any such
company, or (b) any partnership, joint venture or other entity directly or
indirectly controlled by, controlling, or under common control of, to the extent
of fifty percent (50%) or more of voting power (or otherwise having power to
control its general activities) by a party to this Agreement, but in each case
only for so long as such ownership or control shall continue.
"cc" shall mean the unit of volume equal to one (1) cubic centimeter.
"COMPETITIVE PRODUCTS" shall mean injectable augmentation products
used in reconstructive plastic surgery by office-based dermatologists and
office-based plastic surgeons.
"CONTRACT YEAR" shall mean each consecutive twelve month period, with
the first Contract Year beginning on January 1, 2000.
"COST OF GOODS SOLD" shall mean LifeCell's manufacturing cost for each
Unit of Product including direct labor, direct material and manufacturing
overhead allocated on a basis consistent with all of LifeCell's finished goods,
but excluding any extraordinary or non-recurring charges, and expenses or costs
related to the start-up of manufacturing of Micronized AlloDerm-TM- in
commercial quantities.
"COST OF GOODS SOLD PERCENTAGE" shall mean the average, for any six (6)
consecutive months, of the Cost of Goods Sold per Unit divided by the Net Sales
Per Unit.
"DATE OF COMMERCIALIZATION" shall mean the calendar date three business
days after LifeCell first ships any Product to OMP.
"DISTRIBUTION AMOUNT" shall mean [***]% of Net Sales, retained by OMP
to offset costs of distribution.
"DOLLAR", "DOLLARS" or "$" shall mean the legal currency of the United
States of America.
"HOLD BACK AMOUNT" shall mean, for the initial Contract Year, the
percentage of the LifeCell Amount equal to OMP's reserve for bad debts, as
determined in accordance with United States generally accepted accounting
principles, expressed as a percentage of OMP's accounts receivable with respect
to the end of the immediately preceding fiscal year. The Initial Hold Back
Amount shall be [***] percent ([***]%). The Hold Back Amount for all subsequent
Contract Years shall mean the percentage of the LifeCell Amount equal to OMP's
Actual Bad Debt (as defined below) directly related to the sale of Product for
the immediately preceding Contract Year expressed as a percentage of OMP's
accounts receivable with respect to the sale of Product. "Actual Bad Debt"
shall mean OMP's customer accounts for the sale of Product for which payments
are one hundred and twenty (120) days or more past due, and actually written off
against OMP's bad debt reserve account.
"IMPROVEMENT" means any information, discovery, creation, derivative
work, invention, or trade secret, whether or not patented or patentable or
copyrighted or copyrightable, respecting the Product or derived from human
cadaveric dermis, that is developed or otherwise acquired by either party, their
Affiliates or any of their respective employees, officers or agents.
"INDEMNIFIABLE DAMAGES" shall mean the sum of all losses, claims,
damages, liabilities, costs, expenses or deficiencies described in Article X.
-2-
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
"INTELLECTUAL PROPERTY" shall mean (i) patents and patent
applications, (ii) trademarks, trade names, service marks and registrations
and applications for registrations thereof (including, but not limited to,
"AlloDerm-Registered Trademark-," "Cymetra-TM-" and analogs thereof), (iii)
copyrights and copyright registrations, (iv) trade secrets and secret
processes, and (v) other Know-How, in each case relating to the Product and
in the United States of America and the Territory.
"JOINT MANAGEMENT COMMITTEE" shall mean the committee formed pursuant
to Article V of this Agreement.
"KNOW-HOW" shall mean such know-how, special knowledge, data, studies,
technical or other information, whether or not patented or patentable, owned or
controlled by LifeCell at any time prior to or during the Term specifically
related to the Product.
"LIFECELL AMOUNT" shall mean the amount of all Payable Sales made by
OMP on behalf of LifeCell in any month reduced by the amounts, if any, retained
by OMP for co-promotion fees due to OMP, as calculated in accordance with
Sections 3.3 and 3.4.
"NET SALES" shall mean the gross revenue recognized from sales of
Product less the amount for returns and allowances as determined in accordance
with generally accepted accounting principles.
"PAYABLE SALES" shall mean the amount of Net Sales, reduced by the
Distribution Amount.
"PRODUCT" shall mean Micronized AlloDerm-TM- and any Improvement.
Upon the granting of any licenses and rights as contemplated by Section 2.4
and executing and delivering any amendment of this Agreement as contemplated
by Section 2.4, such additional products for which such license is granted
shall thereafter also be deemed Product.
"SPECIFICATIONS" shall mean the Product specifications set forth in
Exhibit B annexed hereto and incorporated herein.
"TERRITORY" shall mean only office-based dermatologists and
office-based plastic surgeons throughout the entire world, as may be modified
by mutual agreement of the Parties pursuant to Section 2.3, PROVIDED,
HOWEVER, that LifeCell's customers, as set forth in Exhibit D annexed hereto
and incorporated herein, are specifically excluded from the Territory.
Notwithstanding any other provision of this Agreement, LifeCell shall retain
the exclusive right to distribute Product in Korea and Brazil, with no rights
to transship from these countries, provided that all Product sold into Korea
and Brazil shall be included in the Minimum Annual Sales of Units sold by OMP
pursuant to section 4.1.
"UNIT" shall mean an individual unit of Product packaged in
accordance with specifications provided by OMP from time to time and
reasonably acceptable to LifeCell. One Unit of Micronized AlloDerm-TM- shall
be equal to 330 milligrams of Micronized AlloDerm-TM- measured on a dry
weight basis which is to be reconstituted with one cc of diluent.
-3-
II. GRANT OF RIGHTS
2.1 GRANT OF RIGHTS; TERRITORY. In consideration for the execution
and delivery of this Agreement and the ongoing performance by OMP of its
responsibilities and obligations hereunder, and upon the terms and conditions
set forth herein, LifeCell hereby grants to OMP the exclusive right to
promote, market, distribute and sell Micronized AlloDerm-TM- and any
Improvement thereto in the Territory, consistent with the terms and
conditions set forth herein, throughout the Term (as defined in Section
13.1). Except as expressly set forth herein, the license granted hereby
expressly excludes all other rights, including without limitation, the right
to manufacture any Product.
2.2 INTENTIONALLY DELETED
2.3 ADDITIONAL TERRITORY. In the event the Parties reach agreement
with respect to the terms and conditions of granting OMP the rights to
promote, market, distribute, and sell the Product in any additional market
segment, pursuant to this Section 2.3, the Parties shall amend this Agreement
to incorporate the terms of such additional terms and conditions into this
Agreement; PROVIDED, HOWEVER, the Parties agree that the revenue allocations
as set forth in Article III shall not be changed as a result of such
amendment.
2.4 ADDITIONAL PRODUCTS. LifeCell agrees that it will not enter into
any exclusive agreement with any third party for any rights to promote, market,
distribute and sell any and all new products substantially similar to the
Product (including, without limitation, any new injectable tissue augmentation
products and any new products which are substantially similar to the Product
but offered in a different delivery platform), without first providing ten (10)
days written notice to OMP. OMP may, within five (5) business days of receiving
such notice, provide written notice to LifeCell indicating OMP's interest in
obtaining such exclusive rights. Thereafter, the Parties shall meet and use
reasonable commercial efforts to reach a mutually acceptable agreement. Nothing
contained in this Agreement obligates LifeCell or OMP to enter into such an
agreement and either party may terminate negotiations concerning such an
agreement at its sole and exclusive option.
III. SALES; REVENUE ALLOCATION
3.1 ONE-TIME PAYMENTS. In consideration of the exclusive licenses and
rights set forth in this Agreement, OMP shall pay LifeCell One Million Dollars
($1,000,000), payable as follows:
(a) Four Hundred Thousand Dollars ($400,000) in immediately available
funds on the Effective Date.
(b) Six Hundred Thousand Dollars ($600,000) in immediately available
funds on the later of either (i) June 30, 2000 or (ii) the date
ninety (90) days following the Date of Commercialization;
-4-
3.2 SALES REPRESENTATIVE. OMP shall act as LifeCell's exclusive
representative in the Territory with respect to sales of Product pursuant to
this Agreement. All revenues obtained from the sales of Product pursuant to
this Agreement shall be for the account of LifeCell and all accounts
receivable related to such sales shall be accounts receivable of LifeCell.
The Parties agree that LifeCell will record the Net Sales of Product on
LifeCell's financial statements, but that OMP shall be responsible, at its
sole cost and expense, for billing customers and collecting the accounts
receivable from such customers. OMP shall not, without the prior written
approval of LifeCell, sell any Product to customers that are over fifty-nine
(59) days past due on their accounts. OMP will endeavor to include in its
Product invoice a notation to the effect that the Product is distributed by
OMP as distributor for LifeCell.
3.3 INTENTIONALLY DELETED
3.4 MICRONIZED ALLODERM-TM- REVENUE ALLOCATION. OMP shall be entitled
to a co-promotion fee for sales of Micronized AlloDerm-TM- according to the
following schedule:
------------------------------------------------------- -----------------------------------------------------
Annual Units OMP Co-Promotion fee as a Percentage of
One (1) Unit equals 330 mgs per cc Payable Sales
------------------------------------------------------- -----------------------------------------------------
[***]-[***] [***]%
------------------------------------------------------- -----------------------------------------------------
[***] to [***] [***]%
------------------------------------------------------- -----------------------------------------------------
[***] and above [***]%
------------------------------------------------------- -----------------------------------------------------
The Co-Promotion fee is predicated on a Cost of Goods Sold Percentage
not exceeding [***]%. If the Cost of Goods Sold Percentage exceeds [***]%, then
LifeCell's continuing obligation to supply Product under the terms of this
Agreement shall be limited to the 100,000 Units during the succeeding four
calendar quarters. Further, in this event, the parties agree to use commercially
reasonable efforts to re-negotiate the Co-Promotion Fee payable.
3.5 MONTHLY PAYMENTS AND REPORTING. On or before the forty-fifth (45th)
day immediately following the last day of each calendar month during the Term,
OMP shall pay to LifeCell the LifeCell Amount less the Hold Back Amount for that
calendar month. OMP shall, on or before the tenth (10th) day of each month,
provide to LifeCell a written report of Net Sales of Products made for the prior
month, setting forth in reasonably sufficient detail the sales price and Unit(s)
of Product ordered and sold and the calculation of the amounts paid to LifeCell
and the co-promotion fees due and retained by OMP, if any. The payment to
LifeCell pursuant to this Section shall be made by check or by wire transfer of
immediately available funds, pursuant to such written wire transfer instructions
as LifeCell may provide to OMP from time to time during the Term. In addition to
any other remedies available to LifeCell arising out of OMP's payment default,
if any payment is more than fifteen days (15) late, OMP shall pay to LifeCell a
late charge on the overdue balance equal to the lesser of (1) 1 1/2% per month
or (ii) the highest rate permitted by applicable law.
-5-
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
3.6 TRUE-UP OF HOLD BACK AMOUNT. No later than sixty (60) days after
the last day of each Contract Year, OMP shall provide LifeCell with a written
report detailing the Actual Bad Debt incurred by OMP (the "Bad Debt Report").
Such Bad Debt Report shall include, without limitation, information concerning
payment history on applicable OMP customer accounts and a summary of the Actual
Bad Debt amounts (including a calculation of the percentage of Actual Bad Debt
as compared to total gross sales of Product) as of the end of the applicable
Contract Year. If the Actual Bad Debt exceeds the applicable Hold Back Amount,
LifeCell shall, within ten (10) business days after delivery of the Bad Debt
Report, reimburse OMP, in immediately available funds, for the difference
between the Hold Back Amount and the Actual Bad Debt for such Contract Year. If
the Actual Bad Debt does not exceed the Hold Back Amount for such Contract Year,
OMP shall, within ten (10) business days after delivery of the Bad Debt Report,
remit to LifeCell the difference, if any, between the Hold Back Amount and the
Actual Bad Debt. Notwithstanding anything to the contrary contained herein, if
the Hold Back Amount or Actual Bad Debt amount exceeds [***] percent ([***]%)
of the gross sales of Product for any applicable Contract Year, LifeCell may
terminate this Agreement in accordance with Section 13.2.
3.7 PRODUCT STORAGE, HANDLING, TRANSPORT AND RECORDS. OMP shall store,
handle and transport the Product, and prepare, maintain and retain all records
regarding such matters and OMP's distribution of Product in accordance with (i)
all applicable legal requirements then in effect, including without limitation,
the regulations of the United States Food and Drug Administration ("FDA") and
the United States Department of Health and Human Services (21 C.F.R. Part 1270),
(ii) the Guidelines of the American Association of Tissue Banks and (iii) the
specifications and procedures set forth on Exhibit E annexed hereto and
incorporated herein, as such exhibit may be revised from time to time upon
mutual agreement of the Parties or as required by applicable laws, rules or
regulations.
3.8 RECORDS; AUDIT RIGHTS. Each party shall keep books and records
sufficient to verify the accuracy and completeness of all activities in
connection with this Agreement, including without limitation, inventory,
shipping and delivery, storing, handling, transport, costs, sales, purchase and
invoice records relating to the Product. Such books and records shall be
preserved for a period not less than ten (10) years after they are created
during and after the Term. Either party may, upon not less than fifteen (15)
business days advance written notice, audit all the books and records of the
other party relating to this Agreement at a single United States location to
verify the accuracy of such party's accounting. Any audit performed pursuant to
this Section 3.8 shall be at expense of the party conducting such audit, unless
it reveals a underpayment or overpayment of five per cent (5%) or more in favor
of the audited party for any Contract year, in which case the audited party
shall reimburse the auditing party for the actual costs of such audit. Such
audit may be performed by any employee of the requesting party as well as by any
attorney or licensed certified public accountant designated by the requesting
party, upon not less than fifteen (15) business days advance notice, during
regular business hours, and in a manner that shall not unreasonably interfere
with such party's normal business operations. Each party shall conduct no more
than one (1) audit during any Contract Year, PROVIDED, HOWEVER, that such audit
shall not be limited to the current Contract Year, but shall be limited to the
period since the completion of the immediately preceding audit, if any. If an
audit reveals any underpayment by OMP to LifeCell, OMP shall pay LifeCell the
amount of such
-6-
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
underpayment within five (5) days of written notification of such
underpayment. If the audit reveals that OMP has made an overpayment to
LifeCell, the amount overpaid will be, at the option of OMP, returned
forthwith to OMP or credited to the next such payment or payments due OMP
from LifeCell.
IV. MINIMUM SALES AMOUNTS
4.1 MICRONIZED ALLODERM-TM-. On or before the last day of each
Contract Year set forth in the chart below, OMP shall attain either (i) the
Minimum Annual Sales amount of Micronized AlloDerm-TM- within that specific
Contract Year as set forth in the table below, or (ii) attain the Total
Cumulative Units of Micronized AlloDerm-TM- sold by the last day of the
Contract Year, as set forth in the table below, provided, however, that if
the Date of Commercialization does not occur on or before June 30, 2000, the
amounts set forth in the table below for Year One, Year Two and the Total
Cumulative Units Sold for Years Two, Three, Four and Five will be reduced to
the amount which is prorated on an annual basis for each day after June 30,
2000 until the actual Date of Commercialization in order to take into account
the lesser time available for OMP to achieve the minimum amounts set forth
below.
--------------------------------- --------------------------------------- -------------------------------
Contract Year Minimum Annual Sales Total Cumulative
Units Sold Units Sold
--------------------------------- --------------------------------------- -------------------------------
Year One [***] [***]
--------------------------------- --------------------------------------- -------------------------------
Year Two [***] [***]
--------------------------------- --------------------------------------- -------------------------------
Year Three [***] [***]
--------------------------------- --------------------------------------- -------------------------------
Year Four [***] [***]
--------------------------------- --------------------------------------- -------------------------------
Year Five [***] [***]
--------------------------------- --------------------------------------- -------------------------------
4.2 FAILURE TO ATTAIN MINIMUM LEVELS. In the event that OMP fails to
meet the obligations set forth in Section 4.1 in any specific Contract Year,
OMP, shall pay to LifeCell in immediately available funds, not later than
thirty (30) after the last day of such Contract Year, [***]% of the
difference between (1) the LifeCell Amount that would have been due to
LifeCell for and as of the last day of such Contract Year had the obligations
set forth in Sections 4.1 been achieved by OMP (the "Minimum Sales Payment")
and (2) any LifeCell Amount actual paid to LifeCell in respect of such
Contract year. In the event that OMP fails to pay to LifeCell an amount equal
to or greater than the Minimum Sales Payment in any Contract Year, LifeCell,
at its sole and exclusive option, may (i) immediately terminate the exclusive
rights granted to OMP in Section 2.1, with such exclusive rights becoming
immediately non-exclusive, or (ii) terminate this Agreement in accordance
with Section 13.2.
4.3 COMPETITIVE PRODUCTS. If, in any Contract Year, the Net Sales of
Competitive Products offered by OMP exceeds twenty-five percent (25%) of the sum
of total sales of the Product by OMP and the total sales of Competitive
Products offered by OMP, LifeCell, at its
-7-
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
sole and exclusive option, may immediately terminate the exclusive rights
granted to OMP in Section 2.1, with such exclusive rights becoming
immediately non-exclusive.
V. JOINT MANAGEMENT COMMITTEE
5.1 STRUCTURE; SCOPE OF RESPONSIBILITY. Within thirty (30) days after
the Effective Date, the Parties shall establish a Joint Management Committee
with an equal number of members from OMP and LifeCell. The Joint Management
Committee will consist of four (4) persons. Each party shall provide the other
party with written notice of the two (2) representatives that such party is
appointing to serve on the Joint Management Committee, and each party shall
retain sole authority to remove its representatives from the Joint Management
Committee and to appoint successors, by providing written notice to the other
party. The Joint Management Committee will facilitate a sharing of information
related to the Product and the respective obligations of the Parties pursuant
to this Agreement. The Joint Management Committee shall have the responsibility
to coordinate the creation of an annual marketing plan and certain activities of
the Parties pursuant to this Agreement, including those related to the
marketing, sales and co-promotion of the Product, and such other matters as the
Parties may mutually agree upon from time to time. Furthermore, the Joint
Management Committee shall use commercially reasonable efforts to set the Price
for the Product.
5.2 DETERMINATION OF MARKET ENTRY. Within ninety (90) days after the
Effective Date, the Parties shall meet, at a date, time and location to be
designated by the Joint Management Committee, to evaluate the feasibility,
timing and requirements for market entry to introduce Micronized
AlloDerm-TM- into some or all of the countries outside of the United States
that contain significant market opportunities for the sale of the Product.
5.3 PRODUCT CLASSIFICATION. As of the Effective Date, the FDA has
classified the Product as banked human tissue. The Parties acknowledge and
agree that, under the Federal Food, Drug and Cosmetic Act and regulations
promulgated thereunder, the FDA could at some future time determine that the
Product is a medical device for the intended uses contemplated in this
Agreement rather than human tissue. The Parties also acknowledge and agree that
LifeCell does not warrant that the Product currently meets or in the future will
meet medical device regulatory requirements, including without limitation, that
the Product will not have obtained premarket approval. The Parties further
acknowledge and agree that the FDA's imposition of medical device regulatory
requirements would be substantially more burdensome and costly than the FDA's
human tissue regulatory requirements and that, among other things, the FDA could
require that a party or the Parties take certain actions with respect to the
Product regarding premarket approval, commercial distribution and regulatory
requirements that could have a material impact on the obligations of the Parties
hereunder. In the event that the Joint Management Committee decides to recommend
a change to the regulatory classification, the Joint Management Committee shall
be responsible for recommending the extent of clinical testing and the
regulatory strategy for the Products. Notwithstanding anything contained herein
to the contrary, the Parties acknowledge and agree that LifeCell shall not be
under any obligation under this Agreement to meet or otherwise satisfy the
medical device regulatory requirements. In the event that the FDA undertakes any
action altering the regulatory classification of the Product,
-8-
and such action has a material adverse effect on the rights or obligations of
the Parties pursuant to this Agreement (including, without limitation, (a)
the commercial viability of any Product and (b) the legal authority or
ability of either party to perform its obligations pursuant to this
Agreement), the Parties' obligations pursuant to this Agreement with respect
to such adversely affected Product shall, in the sole discretion of LifeCell,
be voided or alternatively suspended for so long as the commercial viability
of such Product is affected and the various rights related to such Product
(including those of exclusivity) granted to OMP in this Agreement shall be
extended for a period of time equal to the length of time that such Product
was adversely affected.
VI. QUALITY ASSURANCE AND ADVERSE EVENT REPORTING.
6.1 QUALITY COMPLAINTS. Product quality complaints received by OMP
shall be forwarded upon receipt to a quality assurance representative to be
designated by LifeCell. LifeCell retains sole responsibility to investigate
these complaints throughout the Term and to provide OMP with a follow-up report
and required corrective actions, if any, within thirty (30) days of receipt of
such notice.
6.2 ADVERSE EVENTS. Adverse event reports received by OMP shall be
forwarded upon receipt to LifeCell's designated quality assurance
representative. LifeCell has sole responsibility to fulfill the appropriate
regulatory and reporting requirements related to the adverse event reports
throughout the Term.
6.3 COMPLAINTS. In the event that LifeCell or OMP receives any
complaint, claim or adverse event report relating to the Product, including
notices from the FDA regarding any alleged regulatory non-compliance of such
Product or the marketing of such Product, such party shall, within ten (10)
days following receipt of such notices, or such shorter period as may be
required by applicable laws, rules or regulations, provide to the other party
all information contained in such complaint, report or notice and any
additional information relating thereto as may reasonably be requested.
6.4 REGULATORY NOTICES. Each of LifeCell and OMP shall promptly, but
in no event more than five (5) days following the receipt thereof, notify the
other party and provide to such party a copy or transcription, if available,
of any communication received from a regulatory agency relating to the
Product, the marketing thereof, of any matter related thereto.
6.5 AUDIT OF ADVERSE EVENT REPORTS AND PRODUCT RECALL RECORDS:
(a) Upon reasonable notice and during regular business hours, OMP
shall make available the records relating to quality
complaints referred to in Section 6.1, adverse events referred
to in Section 6.2, complaints referred to in 6.3, and
regulatory notices referred to in Section 6.4 for audit at
LifeCell's expense by independent representatives selected by
LifeCell or qualified LifeCell employees to verify compliance
with the applicable provisions hereof.
-9-
(b) Upon reasonable notice and during regular business hours,
LifeCell shall make available the records relating to quality
complaints referred to in Section 6.1, adverse events referred
to in Section 6.2, complaints referred to in 6.3, and
regulatory notices referred to in Section 6.4 for audit at
OMP's expense by independent representatives selected by OMP
or qualified OMP employees to verify compliance with the
applicable provisions hereof.
VII. MARKETING, SALES AND CLINICAL TRIALS.
7.1 LIFECELL RIGHTS AND RESPONSIBILITY. In the event the Joint
Management Committee is unable to agree upon the price of the Product, LifeCell
shall have the sole right to set the price for the Product, and further LifeCell
shall have the sole right to review and approve any preclinical and clinical
activities undertaken by OMP with respect to the Product.
7.2 OMP RESPONSIBILITY. OMP shall, at its sole cost and expense,
make reasonable efforts to maintain sufficient promotional, marketing, sales,
and distribution capacity to meet the demands of the marketplace for the
Products and to promote and market the Micronized AlloDerm-TM- in the
Territory, including without limitation:
(a) the creation, preparation and production of promotional
materials related to the Product;
(b) the creation and implementation of an advertising campaign to
promote the Product;
(c) maintaining and compensating a reasonably sufficient number of
qualified salespersons to promote and market the Micronized
AlloDerm-TM- in the Territory.
7.3 PRODUCT PACKAGING. Products manufactured and delivered pursuant
to this Agreement shall be labeled in a manner to indicate that the Product
is distributed by OMP for LifeCell and such Product shall be packaged in a
separate trade dress to facilitate product tracking. The Parties agree that
the brand name for the Micronized AlloDerm-TM- shall be "Cymetra-TM-." All
right, title and interest in the name "Cymetra-TM-" shall reside in LifeCell,
and OMP expressly agrees that it neither has nor shall it acquire rights in
the name "Cymetra-TM-" except as expressly set forth in this Agreement.
Within thirty (30) days following the Effective Date, the Parties shall use
diligent commercial efforts to reach mutual agreement on the final packaging
for Product to be distributed pursuant to this Agreement.
7.4 LIFECELL USE OF MARKETING MATERIALS. OMP, upon LifeCell's request,
shall make the Marketing Materials (as defined in Section 7.5) produced pursuant
to this Article VII available to LifeCell for use in conjunction with the
promotion, marketing, sales and distribution of the Product, and to remove
OMP's name from such Marketing Materials. OMP shall provide the Marketing
Materials to LifeCell at the actual cost of producing such materials, as
incurred by OMP.
-10-
7.5 TRADEMARK LICENSES. OMP hereby grants to LifeCell a non-exclusive,
royalty-free right and license to utilize OMP's trademarks, service marks and
trade names as necessary to package and label the Product to be manufactured by
LifeCell pursuant to this Agreement (the "OMP Packaging License"), revocable in
accordance with Section 13.4. LifeCell hereby grants to OMP a non-exclusive,
royalty-free right and license to utilize LifeCell's trademarks, service marks
and trade names as necessary to market, promote, sell and distribute the
Product in the manner contemplated by this Agreement (the "LifeCell Xxxx
License"), revocable in accordance with Section 13.4. The parties acknowledge
and agree that all right, title and interest in and to any trademarks, service
marks or trade names created for any product or Product developed or invented
hereunder shall reside solely in LifeCell.
7.6 PRE-PUBLICATION REVIEW OF MARKETING MATERIALS. All Marketing
Materials (as defined below) are expressly subject to pre-publication review and
approval with respect to, but not limited to, content, style, appearance,
composition, timing, and media. Prior to the distribution or publication of any
materials containing any of LifeCell's trademarks, service marks or trade names
("Marketing Materials") OMP shall provide one copy of such Marketing Materials
to LifeCell for final review and approval (Attention: _________, LifeCell
Corporation, Xxx Xxxxxxxxxx Xxx, Xxxxxxxxxx, XX 00000) at least twenty (20) days
prior to the anticipated publication of such Marketing Materials. LifeCell
agrees to promptly review such Marketing Materials, and LifeCell's failure to
provide written notice of its objection to the use of any Marketing Materials
within twenty (20) business days of their receipt shall constitute LifeCell's
approval of such Marketing Materials. Notwithstanding anything to the contrary
contained herein, OMP shall not use, distribute or publish anything containing
LifeCell's trademarks, service marks or trade names without the express prior
written consent of LifeCell, provided, however that such consent shall be
exercised consistent with this Section 7.6 and not unreasonably, withheld,
conditioned or delayed.
7.7 MARKETING FOR PERMITTED USES. OMP shall market the Product solely
for those uses for which the Product is permitted to be so marketed pursuant
to FDA and all other applicable legal and regulatory requirements.
VIII. SUPPLY; FORECASTS; ORDERS AND SHIPPING.
8.1 AGREE TO SUPPLY. Consistent with the current accepted Forecast
Document (as defined in Section 8.2) and the terms and conditions set forth in
this Agreement, LifeCell shall supply and deliver to OMP Product in such
quantities as OMP requests during the Term of this Agreement, up to the amount
forecasted for such time frame as set forth in the current Forecast Document.
LifeCell shall deliver ordered Product to OMP on the date requested by OMP in
such purchase order, but in no event shall LifeCell be obligated to ship any
Product within less than thirty (30) days from the date of LifeCell's receipt
of a valid written purchase order from OMP. All orders for Product shall be
made pursuant to written purchase orders signed by an authorized representative
of OMP and delivered to LifeCell in accordance with this Article VIII. All
Product received from LifeCell will be held as consigned inventory for
LifeCell. Title to the consigned inventory will remain with LifeCell until the
time that OMP has delivered the Product to the customer and the invoice
therefor, at which time title to such Product shall pass to the customer.
-11-
OMP will return to LifeCell for disposal any expired Product held as consigned
inventory by OMP.
8.2 FORECASTS. Every thirty (30) days during the Term, OMP shall
provide LifeCell with a good faith non-binding running estimate of the
quantity of Product OMP reasonably estimates OMP will order and sell during
each of the next twelve (12) months (but not extending beyond the Term) (the
"Forecast Document"). OMP shall provide its initial forecast within thirty
(30) days after the Effective Date. LifeCell shall have ten (10) days to
review the Forecast Document. If, in LifeCell's good faith judgment, LifeCell
will be unable to meet the amounts set forth in the Forecast Document,
LifeCell shall provide written notice thereof to OMP, and the Parties shall
negotiate in good faith an acceptable amount. If despite reasonable efforts,
LifeCell is unable to supply adequate Product to meet the demands of OMP (as
set forth in the Forecast Document), LifeCell and any third party licensee of
the Product, then LifeCell shall use commercially reasonable efforts to
devise an allocation system of existing supply to be reviewed monthly. If the
Parties are unable to agree upon an allocation of available product, the
matter shall be resolved in accordance with Section XIV.
8.3 ORDERS. Each OMP purchase order shall be in a form compatible
with LifeCell's business form requirements and shall be subject to the terms
and conditions of this Agreement. No printed term or provision contained in
any OMP form or any LifeCell form which is inconsistent with or in addition
to the terms of this Agreement shall be effective to alter the terms of this
Agreement in any way unless agreed to in writing by both Parties. Each
purchase order shall be subject to this Agreement and shall incorporate the
terms and conditions of this Agreement. Each purchase order shall include at
least the following information: the date of the order; the specific Product
ordered; the quantity of each Product ordered; the price of the Product; and
a delivery date for the order.
8.4 CANCELLATION OF ORDERS. OMP may, at no cost, cancel any purchase
order at any time up to twenty (20) days prior to the shipping date set forth on
such purchase order and may reschedule any order at any time up to twenty (20)
days prior to the shipping date set forth on such purchase order.
8.5 DELIVERY. LifeCell shall use commercially reasonable efforts to
ship orders according to the delivery date specified in each purchase order
accepted by LifeCell. Notwithstanding the foregoing, LifeCell shall not be
responsible for any delay in filling any purchase order due to a force majeure
condition as set forth in Section 15.3.
8.6 SHIPPING. LifeCell shall ship Products, F.O.B. destination, to
OMP's warehouse or such other OMP business location in the United States of
America designated by OMP, in a final, packaged form, ready for immediately
delivery to customers.
8.7 INSPECTION; ACCEPTANCE. OMP shall have the right to inspect the
Product prior to sale to customers and shall notify LifeCell in writing of
OMP's rejection of any Product due to the failure of the Product to meet
Specifications. Such written notification by OMP shall include a detailed
description of the test(s) that OMP performed on the Product and the results
of such test(s).
-12-
LifeCell maintains the right to perform its own tests on Product rejected by
OMP to determine if the Product meets Specifications. In the event that
LifeCell's inspection verifies that the rejected Products failed to meet the
applicable Specifications, LifeCell shall, in its sole discretion, either
repair or replace all Product properly rejected under this Section 8.7.
LifeCell shall bear the cost of shipping rejected Product back to LifeCell,
as well as bear the cost of shipping replacement Product to OMP under this
Section 8.7. In the event that LifeCell's inspection indicates that the
Product does meet the applicable Specifications, LifeCell shall provide the
results of its tests to OMP. In the event that the Parties are unable to
reach agreement concerning Product rejected by OMP and which Product
LifeCell's tests indicate conforms to applicable specifications, either party
may invoke the dispute resolution procedure set forth in Article XIV.
IX. REPRESENTATIONS AND WARRANTIES; RELATED MATTERS; LIMITATION OF
LIABILITY
9.1 MUTUAL REPRESENTATIONS AND WARRANTIES. Each of the Parties
represents and warrants to the other that:
(a) it is duly organized, validly existing and in good standing in
accordance with the laws of its jurisdiction of organization;
(b) it has all requisite legal and corporate power and authority
to enter into and perform its obligations under this
Agreement;
(c) it has duly authorized the entry into and performance of its
obligations under this Agreement by all requisite corporate
actions;
(d) when executed by each of the Parties hereto, this Agreement
shall be a legal, valid and binding obligation of such party
enforceable in accordance with its terms, subject to
bankruptcy, insolvency and similar laws affecting creditors'
rights generally and general principles of equity;
(e) its execution and delivery and performance of its obligations
under this Agreement do not breach, violate, conflict with or
contravene in any material respect (i) its organizational
documents, (ii) any laws, rules, regulations, orders,
judgments or decrees applicable to or binding upon it or its
property, or (iii) any other agreement, instrument, mortgage,
indenture, contract, license or other document to which it is
a party or by which it is bound;
(f) it has obtained all governmental and third party consents and
made all filings and notices required in connection with its
execution, delivery and performance of this Agreement, and all
such consents, filings and notices remain in full force and
effect; and
(g) it will comply in all material respects with all applicable
laws, rules and regulations in the conduct of its
responsibilities and activities under this Agreement.
9.2 ADDITIONAL LIFECELL REPRESENTATIONS AND WARRANTIES. LifeCell
represents and warrants to OMP that:
-13-
(a) all Product will conform in all material respects to the
Specifications;
(b) LifeCell is and will remain in substantial compliance
with good manufacturing practices;
(c) LifeCell has, and throughout the Term at all times shall
maintain, at LifeCell's sole expense, sufficient right, title
and interest in all Intellectual Property (other than the OMP
Packaging License and other Intellectual Property owned by
OMP) necessary to produce and license the Product for sale in
the Territory contemplated by this Agreement;
(d) LifeCell holds each item of registered or registrable
Intellectual Property (including, without limitation, patents,
trademarks, trade names, and applications for any of the
foregoing (including the status of such applications and any
rejections or challenges thereof)) listed on Exhibit A;
(e) there are no interference, opposition or cancellation
proceedings pending or threatened against any of the
Intellectual Property listed on Exhibit A;
(f) no claim, suit or action to which LifeCell is a party or which
is known to LifeCell is pending or, to LifeCell's knowledge
after due inquiry, threatened alleging that any Product is
infringing or would infringe upon the Intellectual Property
rights of others; and
(g) the Product and the licenses and rights granted or purported
to be granted to OMP pursuant to this Agreement with respect
thereto do not infringe, violate or otherwise impair any
Intellectual Property right or any other proprietary right of
any third party in the United States.
9.3 ADDITIONAL OMP REPRESENTATIONS AND WARRANTIES. OMP represents and
warrants to LifeCell that:
(a) the OMP Packaging License includes all the Intellectual
Property rights necessary for LifeCell to produce the
packaging and labeling required by this Agreement;
(b) it will store, handle and transport the Products, and prepare,
maintain and retain all records regarding such matters and its
distribution of Product in accordance with (i) all applicable
legal requirements then in effect, including without
limitation, the regulations of the FDA and the United States
Department of Health and Human Services (21 C.F.R. Part 1270),
(ii) the Guidelines of the American Association of Tissue
Banks and (iii) the specifications and procedures set forth on
Exhibit E annexed hereto and incorporated herein, as such
exhibit may be revised from time to time upon mutual agreement
of the Parties and in compliance with appropriate state
statutes and regulations.
9.4 DISCLAIMER OF DAMAGES. WITH THE EXCEPTION OF THE INDEMNIFICATION
OBLIGATIONS SET FORTH IN ARTICLE X, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO
THE OTHER PARTY FOR ANY SPECIAL, COLLATERAL, INDIRECT, EXEMPLARY, INCIDENTAL OR
CONSEQUENTIAL
-14-
DAMAGES, INCLUDING BUT NOT LIMITED TO, LOSS OF GOODWILL, LOSS OF PROFITS, OR
LOSS OF USE, FOR BREACH OF ANY OF THE PROVISIONS OF THIS AGREEMENT,
REGARDLESS OF WHETHER SUCH LIABILITY IS BASED ON BREACH OF CONTRACT, TORT,
STRICT LIABILITY OR OTHERWISE, AND EVEN IF ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES.
X. INDEMNIFICATION
10.1 SCOPE OF INDEMNITY. Each party (the "Indemnifying Party")
agrees to indemnify, defend and hold the other party and any of its parent
companies and Affiliates, and the present and former officers, members,
shareholders, directors, employees, representatives, attorneys, insurers and
agents of any of these, and their successors, heirs and assigns (each, an
"Indemnified Party") harmless from and against any and all losses,
liabilities, claims, costs, damages and expenses (including, without
limitation, fines, forfeitures, attorneys' fees, disbursements and
administrative or court costs) arising directly or indirectly out of any
breach or alleged breach of its representations and warranties in this
Agreement. Each party further agrees to indemnify defend and hold the other
party, its parent, subsidiaries and affiliates, and each of their respective
present and former officers, members, shareholders, directors, employees,
representatives, attorneys, agents, successors heirs and assigns (each, an
"Indemnified Party"), harmless from any and all losses, liabilities, claims,
costs, damages and expenses (including, without limitation, fines,
forfeitures, attorneys' fees, disbursements and administrative or court
costs) arising directly or indirectly out of (a) the handling or sale of the
Product by the Indemnifying Party and (b) the manufacture of the Product by
the Indemnifying Party. LifeCell further agrees to indemnify defend and hold
OMP, its parent, subsidiaries and affiliates, and each of their respective
present and former officers, members, shareholders, directors, employees,
representatives, attorneys, agents, successors heirs and assigns (each, an
"Indemnified Party"), harmless from any and all losses, liabilities, claims,
costs, damages and expenses (including, without limitation, fines,
forfeitures, attorneys' fees, disbursements and administrative or court
costs) arising directly or indirectly out of the use of the Product by third
parties, other than those that arise out of OMP's breach of its obligations
under Section 3.7 of this Agreement or any material misprepresentation
relating to any Product made by OMP.
10.2 PROCESS. Any Indemnified Party seeking indemnification shall
notify the Indemnifying Party of the indemnified claim or action in writing
within a reasonably prompt time. Upon receipt of notice of the assertion of a
claim, the Indemnifying Party shall employ counsel reasonably acceptable to the
Indemnified Party and shall assume defense of the claim. The Indemnified Party
shall have the right to employ separate counsel and to participate in (but not
control) any such defense. The fees and expenses of such separate counsel shall
be at the expense of the Indemnified Party unless (a) the Indemnified Party has
been given a formal opinion by its counsel that there is a conflict of interest
between it and the Indemnifying Party, or (b) the Indemnifying Party has not in
fact employed counsel to assume defense of the action within a reasonable time
following receipt of the notice given pursuant to this Agreement, in each of
which cases the fees and expenses of such counsel shall be at the expense of the
Indemnifying Party. The Indemnifying Party agrees that it will not consent to
the entry of any judgment or enter into any settlement which does not include as
an unconditional term thereof
-15-
the giving by the claimant or plaintiff to the Indemnified Party a release
from all liability with respect to the claim. Each Indemnified Party shall
reasonably cooperate in the defense of any claim for which indemnification is
required and shall furnish such records, information, testimony and attend
such conferences, discovery proceedings, hearings, trials and appeal as may
reasonably requested by the Indemnifying Party.
10.3 IP INFRINGEMENT. If any claim involving infringement, violation
or impairment of any kind of Intellectual Property for which LifeCell is
obligated to indemnify OMP pursuant to this Article X is resolved in a manner
that precludes LifeCell from granting any right included in the Intellectual
Property, LifeCell will, at LifeCell's expense:
(a) procure such license as is necessary for OMP's past
rights and future rights to continue to exercise all
rights granted with respect to the Product under
this Agreement;
(b) replace or modify the allegedly infringing item(s) to
avoid the infringement, without materially impairing
performance or compliance with the Product's
specifications to OMP's reasonable satisfaction, or
(c) if neither the procuring of such a license nor the
replacement or modification as above-described are
economically practicable, accept return of all the
Product delivered to OMP which have not been sold
to customers and refund OMP all its necessary and
reasonable costs incurred as a result of LifeCell's
inability to procure the past rights for OMP to
continue to exercise all rights granted herein.
10.4 RIGHT TO SET-OFF. Each Indemnified Party shall be entitled to
offset against any obligations owed by such party to the Indemnifying Party
the sum of all Indemnifiable Damages that such Indemnified Party is entitled
to pursuant to this Article X.
10.5 INSURANCE. Each party shall maintain at its expense commercial
general liability insurance in a principal amount of not less than the
coverage generally maintained by companies of similar size in its industry.
Each party shall also maintain a product liability policy relating to any use
of the Product at any time after the date of this Agreement with coverage of
not less than One Million Dollars ($1,000,000) per occurrence and Ten Million
Dollars ($10,000,000) in the aggregate. Each of the policies required under
this Section 10.5 and maintained by any party shall name the other party as
an additional insured and require the insurer to provide at least thirty (30)
days written notice to such other party before any cancellation or material
change to the limits, deductibles or terms of such policies. Within thirty
(30) days after the date of this Agreement, each party shall furnish to the
other party certificates evidencing its insurance, such other party's
designation as additional insured, and such notice requirement. Any party may
elect to suspend its performance under this Agreement until any insurance
required to be maintained by the other party is in place and such
certificates of coverage are provided.
-16-
XI. CONFIDENTIAL INFORMATION
11.1 CONFIDENTIAL INFORMATION. Each party acknowledges that it and
its employees or agents may, in the course of this Agreement, be exposed to
or acquire information which is proprietary or confidential to the other
party ("Confidential Information"). Confidential Information hereunder shall
include, if disclosed orally and such disclosure contains an oral statement
that the information being disclosed is confidential or proprietary (provided
such statement is followed by a writing delivered to the receiving party
within thirty (30) days of the initial disclosure which indicates the date of
disclosure and a non-confidential description of the Confidential Information
disclosed, or if disclosed in writing or visually, a legend or some other
clear written indication that the information disclosed is confidential or
proprietary: (a) marketing, sales, financial, scientific, and other
non-public and/or proprietary information concerning the Product, projects,
business and operations of such party and its Affiliates including the
manufacture, use, or sale of the Product; (b) any technical information,
design, process, procedure, formula, improvement, and other data relating to
the development or production of the Product; and (c) the terms and
conditions of this Agreement. Confidential Information shall not include any
information that is: (a) generally known or available to the public through
no act of the receiving party, (b) already known to the receiving party at
the time of receiving the Confidential Information, or (c) furnished to the
receiving party by a third party with the right to do so. In the event that
any disclosure of Confidential Information is required by a governmental
authority or by order of a court of competent jurisdiction, the disclosing
party shall, prior to disclosure and as soon as practicable by the best
available means, notify the other party thereof in an effort to permit the
disclosing party adequate opportunity to object to the disclosure order or
take other action to preserve the confidentiality of the Confidential
Information.
11.2 NO ADDITIONAL RIGHTS. The furnishing of Confidential
Information by one party to the other shall not constitute any grant, option
or license to the other under any patent or other rights now or hereafter
held by the furnishing party.
11.3 LENGTH OF SURVIVAL. The provisions of this Article XI shall
survive termination of this Agreement and continue for a period of three (3)
years.
XII. PRODUCT RECALLS; COMPLAINTS AND REGULATORY NOTICES
12.1 RESPONSIBILITY FOR RECALL. In the event any Product must be
recalled from the channel of distribution by reason of failure to meet any
requirements of law or otherwise, OMP shall have the sole responsibility to
effect the recall. LifeCell shall use its best efforts to cooperate with OMP in
implementing any such recalls to the extent such cooperation is necessary to
effect the recall.
12.2 RESPONSIBILITY FOR REIMBURSEMENT. In the event the recall results
from or is caused by an act or omission by OMP, OMP shall reimburse LifeCell for
any costs and/or expenses reasonably expended by LifeCell as a consequence of
the recall. Without limiting the general nature of the foregoing, OMP shall bear
the cost of any Product involved in such recall. In the event the recall
results from or is caused by an act or omission by LifeCell, LifeCell shall
-17-
reimburse OMP for any costs and/or expenses reasonably expended by OMP as a
consequence of the recall. Without limiting the general nature of the
foregoing, LifeCell will provide replacement Product for recalled Product
and for any Product that cannot be shipped due to the condition requiring
the recall.
XIII. TERM; RENEWAL; TERMINATION
13.1 TERM. This Agreement shall become effective on the Effective
Date and shall continue for a period of five (5) years (the "Initial Term"),
unless this Agreement is otherwise (a) terminated as provided in this
Agreement, or (b) extended by mutual agreement of the Parties in a written
instrument executed in conformance with the procedure for amending this
Agreement. If OMP meets or exceeds the minimum sales levels described in
Section 4.1, or alternatively, makes the payments to LifeCell described in
Section 4.2 in a timely manner, and is not otherwise in default of its
obligations hereunder, then OMP shall have the right to renew the Agreement
for an additional five (5) year term (a "Renewal Term") by notifying LifeCell
of its intent to renew the Agreement, in writing, at least one hundred and
eighty (180) days prior to the expiration of the Initial Term, in which case
the Minimum Annual Sales Amounts set forth in Article IV shall be increased
by [***] percent ([***]%) annually for the Term. The Initial Term, any mutually
agreed upon extensions, and the Renewal Term(s), if any, shall constitute the
"Term" of this Agreement.
13.2 TERMINATION FOR CAUSE. Either party has the right, but not the
obligation, to terminate this Agreement in the event of a material breach of
this Agreement by the other party, unless such breach is cured within thirty
(30) days of receipt of written notice of such breach.
13.3 TERMINATION DUE TO INSOLVENCY OR BANKRUPTCY. Either party may
terminate this Agreement upon thirty (30) days advance notice if the other
party is declared insolvent or bankrupt by a court of competent jurisdiction,
or a voluntary petition of bankruptcy is filed in any court of competent
jurisdiction by such party, or such party makes or executes an assignment for
the benefit of creditors.
13.4 EVENTS UPON TERMINATION. Upon the termination, expiration or
cancellation of this Agreement, all rights granted by LifeCell to OMP with
respect to the Product or Improvement shall cease, other than the right to
complete the sale of Product then lawfully in its possession. Each party
will remain obligated to pay outstanding amounts due prior to the date of
termination. Each party will promptly return to the other party or destroy
all copies of any Confidential Information, including all notes, abstracts,
and other documents that contain Confidential Information, and will provide
to the other party a written certification from an officer certifying how
such Confidential Information was disposed. The OMP Packaging License and the
LifeCell Xxxx License shall expire upon the expiration, termination or
cancellation of this Agreement.
13.5 SURVIVAL OF TERMINATION. The obligations of the parties under
Articles I, IX, X, XI, XIV and XV shall survive any such expiration,
termination or cancellation, subject to any limitation specified in such
Article and Section.
-18-
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
XIV. ALTERNATIVE DISPUTE RESOLUTION
14.1 DISPUTE RESOLUTION. In order to attempt to resolve any dispute
between the Parties hereunder, and except as otherwise specifically provided
herein to the contrary, as a condition precedent to the non-breaching party
terminating this Agreement under Section 13.2 or as otherwise provided in
this Agreement, or filing a suit, instituting a proceeding or seeking other
governmental resolution in connection with this Agreement, the Parties, with
the help and assistance of the Joint Management Committee, will attempt to
reach a mutually agreeable resolution of the dispute through best efforts
negotiation for a minimum of thirty (30) business days. If the Parties are
unable to reach a mutually agreeable resolution within such thirty (30)
business days, then the Parties shall submit the dispute to a non-binding
mediation for a minimum of an additional sixty (60) business days, utilizing
a single mediator who is a retired judge mutually agreed upon by the Parties.
If the Parties are unable to reach a mutually agreeable resolution within
such ninety (90) business days, either party may exercise its rights
hereunder in the manner selected by such party in order to resolve the
dispute.
XV. MISCELLANEOUS
15.1 PREAMBLE; RECITALS. The Preamble and Recitals set forth above
are intended to be an integral part of this Agreement, and the Preamble and
Recitals (including the definitions set forth therein) are hereby
incorporated by reference.
15.2 NOTICES. Any notices required or permitted to be given
hereunder shall be delivered by personal delivery, overnight commercial
courier or by certified mail, return receipt requested, at the address of the
parties specified below, and shall be effective upon receipt. Either party
may at any time designate another person or address for the receipt of notice
by notifying the other party in accordance with this Section 15.2.
If to LifeCell: If to OMP:
LifeCell Obagi Medical Products, Inc.
One Millenium Way 000 Xxxxxx Xxxxx
Xxxxxxxxxx, XX 00000 Xxxx Xxxxx, XX 00000
Attn: Xxxx Xxxxxx, CEO Attn: Xxxxxx Xxxx
-19-
With a copy to:
Xxxxxxxxxx Xxxxxxx, PC Xxxxxxx Xxxx & Xxxxxxxxx XXX
00 Xxxxxxxx Xxxxxx Xxx Xxxxx Xxxxxxxx Xx, #000
Xxxxxxxxxx, XX 00000 Xxxxxxx, XX 00000
Attn: Xxxxxx X. Xxxxxx, Esq. Attn: Xxx X. Xxxxxxxxx, Esq.
15.3 FORCE MAJEURE. Neither party shall be deemed in default or
otherwise liable under this Agreement due to its inability to perform its
obligations by reason of any fire, earthquake, flood, substantial snowstorm,
epidemic, accident, explosion, casualty, strike, lockout, labor controversy,
riot, civil disturbance, act of public enemy, embargo, war, act of God, or
any municipal, county, state or national ordinance or law, or any executive,
administrative or judicial order (which order is not the result of any act or
omission which would constitute a default hereunder), or any failure or delay
of any transportation, power, or communications system or any other or
similar cause beyond that party's reasonable control.
15.4 GOVERNING LAW. This Agreement and all matters or issues related
this Agreement shall be governed by the laws of the State of New Jersey
without regard to its choice of law or conflict of laws rules.
15.5 ASSIGNMENT. Neither party shall sell, assign, mortgage or
otherwise transfer any of its rights or obligations under this Agreement
without the consent of the other party, such consent not to be unreasonably
withheld, conditioned or delayed, nor shall any of said rights or obligations
be assigned or transferred by operation of law or otherwise without such
consent. Notwithstanding the foregoing, either party may assign this
Agreement in connection with a sale of all or substantially all of its assets
or equity interests, or to any Affiliate. In the event of any permitted
assignment or transfer, the approved assignee shall agree to accept and abide
by all of the terms and conditions of this Agreement.
15.6 RELATIONSHIP OF PARTIES: NO JOINT VENTURE. Neither this
Agreement nor the cooperation of the parties contemplated under this
Agreement shall be deemed or construed to create any partnership, joint
venture or other business entity between OMP and LifeCell.
15.7 SEVERABILITY. The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability
of any other provision of this Agreement. In the event that any provision of
this Agreement is determined to be invalid, unenforceable or otherwise
illegal, such provision shall be deemed restated, in accordance with
applicable law, to reflect as nearly as possible the original intentions of
the parties, and the remainder of this Agreement shall remain in full force
and effect.
15.8 WAIVER. No term or condition of this Agreement shall be deemed
waived, and no breach shall be deemed excused, unless such waiver or excuse
is in writing and is executed by the party against whom such waiver or excuse
is claimed.
-20-
15.9 ENTIRE AGREEMENT; AMENDMENTS. This Agreement, including all
Exhibits, contains the entire agreement and understanding between the parties
with regard to the subject matter hereof, and supersedes all prior and
contemporaneous oral or written agreements and representations. Any amendment
of this Agreement shall be in writing and signed by both parties.
15.10 COMMUNICATIONS. Each party agrees that it shall not make any
public announcement regarding the cooperative relationship described in this
Agreement without the prior approval of the other, both as to timing and
substance, such approval not to be unreasonably withheld.
15.11 COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall constitute an original and all of which
taken together shall constitute one and the same Agreement.
-21-
IN WITNESS WHEREOF, the parties, intending to be legally bound, as
described in the Preamble, have caused this Agreement to be executed by their
authorized representatives.
LifeCell Corporation Obagi Medical Products, Inc.
By: /s/ X. Xxxxxx By: /s/ Xxxxxxx Xxxx
-------------------------------- -------------------------------
Name: Xxxx X. Xxxxxx Name: Xxxxxxx X. Xxxx
------------------------------ -----------------------------
Title: President & CEO Title: President & CEO
----------------------------- ----------------------------
-23-
EXHIBIT A
SCHEDULE OF INTELLECTUAL PROPERTY OWNED BY LIFECELL
U.S. Patent No. 5,336,616
"Method for Processing and Preserving Collagen-Based Tissues for
Transplantation" Corresponding Applications filed or issued: AU, CA,
EP, JP
U.S. Application No. 08/759,801
"Method for Processing and Preserving Collagen-Based Tissues for
Transplantation"
U.S. Application No. 09/207,179
"Reconstituted Skin"
PCT Application No. US99/038667
"Method for Processing and Preserving Collagen-Based Tissues"
PCT Application No. US99/13861
"Particulate Acellular Tissue Matrix" (Micronized
ALLODERM-Registered Trademark-)
TRADEMARK PORTFOLIO
LIFECELL-Registered Trademark-
Registration No. 1,475,428
ALLODERM-Registered Trademark-
Registration No. 1,782,561
TRADEMARK PORTFOLIO UNDER CONSIDERATION
MICRONIZED ALLODERM-TM-
CYMETRA-TM-
A-1
EXHIBIT B
--------------------------------------------------------------------------------
LIFECELL CORPORATION, THE WOODLANDS, TEXAS
FINISHED GOOD SPECIFICATION 100A0008
MICRONIZED ALLODERM, 330 MG VIAL Rev. A
LifeCell Part No.: 602001 Page 1 of 2
--------------------------------------------------------------------------------
1 PURPOSE
This specification describes the required characteristics of Micronized
AlloDerm, requirements for raw materials, and, by reference, the process
required to produce, inspect, ship, and track individual pieces to the
customer.
2 APPLICABLE DOCUMENTS
The following documents are referenced in this specification by title:
AATB, STANDARDS FOR TISSUE BANKING
FDA INTERIM RULE, CFR 1270
2.1 Design Documents
111A0001 SKIN, HUMAN, CADAVER
2.2 Manufacturing Documents
002S0014 PACKAGING FOR MICRONIZED ALLODERM
100S0008 MICRONIZED ALLODERM
2.3 Quality Assurance Documents
001S0002 ALLODERM TRACKING
001S0054 QA RELEASE FOR MICRONIZED ALLODERM
3 DESCRIPTION
Micronized AlloDerm is a freeze-dried acellular matrix derived from
papillary and reticular human dermis and is characterized by the
following:
a Dermal and epidermal cells removed, evidenced by histological
analysis
b Collagen bundles are intact, evidenced by electron microscopic
analysis
c Absence of commensal and pathogenic microorganisms per
microbiological testing (method CFR 610.12/Viromed or equivalent)
d Macroscopic appearance should be white to buff-colored and not
exhibit consolidated aggregates that cannot be broken up when the
dry sample is agitated
e Residual moisture content of LESS THAN OR EQUAL TO 5%, evidenced by
residual moisture analysis
4 QUALITY ASSURANCE
4.1 TESTING
All tissue processed for Micronized AlloDerm shall be tested and
accepted/rejected per QA Release for Micronized AlloDerm (001S0054).
4.2 TRACKING
Micronized AlloDerm supplied by LifeCell for transplantation or
testing shall be tracked per AlloDerm Tracking in accordance with FDA
Interim Rule CFR 1270.
Page 2 of 2
5 PACKAGING/LABELING
5.1 PACKAGING
Each dose of Micronized AlloDerm shall be packaged in an autoclaved
siliconized glass vial with a minimum of 330 mg of dry product per
dose.
5.2 LABELING
All package labels (excluding marketing overlabels) shall be capable
of withstanding temperatures of -35DEG.C to +40DEG.C without adverse
effects on the printing or loss of label adhesion to the vials.
6 STORAGE
All Micronized AlloDerm which meets the requirements of the QA Release
for Micronized AlloDerm, and is hence accepted for Finished Goods, shall
be stored in a restricted, temperature-controlled environment (1DEG.C to
10DEG.C) until the time of distribution. All Micronized AlloDerm, which
does not meet the requirements, and is hence rejected, shall be stored in
a separate temperature-controlled environment until such time that the
disposition of such tissue is determined.
FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
------------------------------------------------------------------------------------------------------------------------------------
TNX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TNXAMT NAME ADDRESS CITY STATE ZIP VS L
------------------------------------------------------------------------------------------------------------------------------------
1 4528 99 O PL 101 $ [***] O
2 3689 99 O PL 101 $ O
3 4729 99 O PL 101 $ O
4 4391 99 O PL 101 $ O
5 4298 99 O PL 101 $ O
6 4043 99 O PL 101 $ O
7 4543 99 O PL 101 $ O
8 3832 99 O PL 101 $ O
9 4403 99 O PL 101 $ O
10 3957 99 O PL 101 $ O
11 4397 99 O PL 101 $ O
12 4233 99 O PL 101 $ O
13 3140 99 O PL 101 $ O
14 1387 99 O PL 101 $ O
15 3379 99 O PL 101 $ O
16 4579 99 O PL 101 $ O
17 3218 99 O PL 101 $ O
18 3347 99 O PL 101 $ O
19 3052 99 O PL 101 $ O
20 3245 99 O PL 101 $ O
21 4639 99 O PL 101 $ O
22 4000 99 O PL 101 $ O
23 3599 99 O PL 101 $ O
24 3165 99 O PL 101 $ O
25 3706 99 O PL 101 $ O
26 4395 99 O PL 101 $ O
27 3973 99 O PL 101 $ O
28 3902 99 O PL 101 $ O
29 4488 99 O PL 101 $ O
30 3870 99 O PL 101 $ O
31 4324 99 O PL 101 $ O
32 3161 99 O PL 102 $ O
33 4779 00 X XX 000 X
00 0000 00 X XX 102 $ O
35 4793 00 X XX 000 X
00 0000 00 X XX 102 $ O
37 3617 99 O PL 102 $ O
38 4836 00 X XX 000 X
00 0000 00 X XX 102 $ O
40 4792 00 X XX 000 X
00 0000 00 X XX 103 $ O
*** Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
------------------------------------------------------------------------------------------------------------------------------------
TAX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP VS L
------------------------------------------------------------------------------------------------------------------------------------
42 3732 00 X XX 000 $ [***] [***] 0
43 3564 99 O PL 104 $ 0
44 3964 99 O PL 104 $ 0
45 2951 99 O PL 104 $ 0
46 4037 99 O PL 104 $ 0
47 4612 99 O PL 104 $ 0
48 3448 99 O PL 104 $ 0
49 4451 99 O PL 104 $ 0
50 4565 99 O PL 104 $ 0
51 3071 99 O PL 104 $ 0
52 4578 99 O PL 104 $ 0
53 2889 99 O PL 104 $ 0
54 4704 99 O PL 105 $ 0
55 4359 99 O PL 105 $ 0
56 3049 99 O PL 105 $ 0
57 4004 99 O PL 105 $ 0
58 3655 99 O PL 105 $ 0
59 4439 99 O PL 105 $ 0
60 4036 99 O PL 105 $ 0
61 4412 99 O PL 105 $ 0
62 4056 99 O PL 105 $ 0
63 1413 99 O PL 105 $ 0
64 4722 99 O PL 105 $ 0
65 2556 99 O PL 105 $ 0
66 3887 99 O PL 105 $ 0
67 4159 99 O PL 105 $ 0
68 2962 99 O PL 105 $ 0
69 4082 99 O PL 105 $ 0
70 2887 99 O PL 105 $ 0
71 4363 99 O PL 105 $ 0
72 1467 99 O PL 105 $ 0
73 3639 99 O PL 105 $ 0
74 4060 99 O PL 105 $ 0
75 4156 99 O PL 105 $ 0
76 4510 99 O PL 105 $ 0
77 2936 99 O PL 105 $ 0
78 4350 99 O PL 105 $ 0
79 3770 99 O PL 105 $ 0
80 4126 99 O PL 106 $ 0
81 3882 99 O PL 106 $ 0
82 2968 99 O PL 107 $ 0
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
------------------------------------------------------------------------------------------------------------------------------------
TAX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP VS L
------------------------------------------------------------------------------------------------------------------------------------
83 4854 00 X XX 000 $ [***] [***] 0
84 4549 99 O PL 107 $ 0
85 2623 99 O PL 108 $ 0
86 2882 99 O PL 108 $ 0
87 4311 99 O PL 108 $ 0
88 2988 99 O PL 108 $ 0
89 3585 99 O PL 108 $ 0
90 4725 99 O PL 108 $ 0
91 4758 99 O PL 108 $ 0
92 2997 99 O PL 108 $ 0
93 3357 99 O PL 108 $ 0
94 2009 99 O PL 108 $ 0
95 1341 99 O PL 108 $ 0
96 4422 99 O PL 108 $ 0
97 4585 99 O PL 108 $ 0
98 2910 99 O PL 108 $ 0
99 3002 99 O PL 108 $ 0
100 4306 00 X XX 000 $ 0
101 3802 00 X XX 000 $ 0
102 3394 00 X XX 000 $ 0
103 3374 00 X XX 000 $ 0
104 3145 00 X XX 000 $ 0
105 4356 00 X XX 000 $ 0
106 4194 00 X XX 000 $ 0
107 4234 00 X XX 000 $ 0
108 3124 00 X XX 000 $ 0
109 4512 00 X XX 000 $ 0
110 3662 00 X XX 000 $ 0
111 3851 00 X XX 000 $ 0
112 4824 00 X XX 000 $ 0
113 3927 00 X XX 000 $ 0
114 4376 00 X XX 000 $ 0
115 4053 00 X XX 000 $ 0
116 4844 00 X XX 000 $ 0
117 3122 00 X XX 000 $ 0
118 1323 00 X XX 000 $ 0
119 4244 00 X XX 000 $ 0
120 4114 00 X XX 000 $ 0
121 3073 00 X XX 000 $ 0
122 4751 00 X XX 000 $ 0
123 4149 99 O PL 109 $ 0
*** Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
------------------------------------------------------------------------------------------------------------------------------------
TNX CUST SUM OF O
# CUST ID YR TYPE SPECIALTY TER TNXAMT NAME ADDRESS CITY STATE ZIP VSL
------------------------------------------------------------------------------------------------------------------------------------
124 3749 00 X XX 000 $ [***] 0
125 4353 99 O PL 109 $ 0
126 4643 00 X XX 000 $ 0
127 3322 00 X XX 000 $ 0
128 3612 00 X XX 000 $ 0
129 4217 00 X XX 000 $ 0
130 4220 00 X XX 000 $ 0
131 3536 00 X XX 000 $ 0
132 3813 00 X XX 000 $ 0
133 3949 00 X XX 000 $ 0
134 3074 00 X XX 000 $ 0
135 3586 00 X XX 000 $ 0
136 3842 00 X XX 000 $ 0
137 3605 00 X XX 000 $ 0
138 4765 99 O PL 202 0
139 4717 00 X XX 000 $ 0
140 4317 00 X XX 000 $ 0
141 4463 00 X XX 000 $ 0
142 3886 00 X XX 000 $ 0
143 4461 00 X XX 000 $ 0
144 4185 00 X XX 000 $ 0
145 3562 00 X XX 000 $ 0
146 4572 00 X XX 000 $ 0
147 4161 00 X XX 000 $ 0
148 4335 00 X XX 000 $ 0
149 3632 00 X XX 000 $ 0
150 4640 00 X XX 000 $ 0
151 3669 00 X XX 000 $ 0
152 4111 00 X XX 000 $ 0
153 3481 00 X XX 000 $ 0
154 4470 00 X XX 000 $ 0
155 3567 00 X XX 000 $ 0
156 3327 00 X XX 000 $ 0
157 4088 00 X XX 000 $ 0
158 3998 00 X XX 000 $ 0
159 3890 99 O DM 202 $ 0
160 4044 00 X XX 000 $ 0
161 4731 00 X XX 000 $ 0
162 3987 00 X XX 000 $ 0
163 4448 00 X XX 000 $ 0
164 3602 99 O PL 204 $ 0
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
------------------------------------------------------------------------------------------------------------------------------------
TNX CUST SUM OF O
# CUST ID YR TYPE SPECIALTY TER TNXAMT NAME ADDRESS CITY STATE ZIP VSL
------------------------------------------------------------------------------------------------------------------------------------
165 3516 00 X XX 000 $ [***] 0
166 3845 99 O PL 204 $ 0
167 4216 00 X XX 000 $ 0
168 4007 00 X XX 000 $ 0
169 4592 00 X XX 000 $ 0
170 4485 00 X XX 000 $ 0
171 3954 00 X XX 000 $ 0
172 4224 00 X XX 000 $ 0
173 3556 00 X XX 000 $ 0
174 4521 00 X XX 000 $ 0
175 4638 00 X XX 000 $ 0
176 3788 00 X XX 000 $ 0
177 3500 00 X XX 000 $ 0
178 3804 00 X XX 000 $ 0
179 4806 00 O PL 204 0
180 4519 00 X XX 000 $ 0
181 3900 00 X XX 000 $ 0
182 3691 00 X XX 000 $ 0
183 3779 00 X XX 000 $ 0
184 3103 00 X XX 000 $ 0
185 4603 00 O PL 204 0
186 3750 00 X XX 000 $ 0
187 3597 00 X XX 000 $ 0
188 3953 00 X XX 000 $ 0
189 4573 00 X XX 000 $ 0
190 4827 00 O PL 204 0
191 4084 00 X XX 000 $ 0
192 3961 00 X XX 000 $ 0
193 4398 00 X XX 000 $ 0
194 4257 00 X XX 000 $ 0
195 3422 00 X XX 000 $ 0
196 3211 00 X XX 000 $ 0
197 3554 00 X XX 000 $ 0
198 9999 00 O PL 206 0
199 4249 00 X XX 000 $ 0
200 4365 00 X XX 000 $ 0
201 4396 00 X XX 000 $ 0
202 3741 99 O PL 206 $ 0
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
------------------------------------------------------------------------------------------------------------------------------------
TAX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP VS L
------------------------------------------------------------------------------------------------------------------------------------
203 2891 00 X XX 000 $ [***] [***] 0
204 4794 00 O PL 206 0
205 4709 00 X XX 000 $ 0
206 2725 00 X XX 000 $ 0
207 3772 00 X XX 000 $ 0
208 2566 00 X XX 000 $ 0
209 4649 00 X XX 000 $ 0
210 4817 00 O PL 207 0
211 1206 00 X XX 000 $ 0
212 2587 00 X XX 000 $ 0
213 2466 00 X XX 000 $ 0
214 4814 00 O PL 207 0
215 4791 00 X XX 000 0
000 0000 00 X XX 207 $ 0
217 4856 00 O PL 207 0
218 4402 00 X XX 000 $ 0
219 4790 00 O PL 208 0
220 2995 00 X XX 000 $ 0
221 2859 00 X XX 000 $ 0
222 2635 00 X XX 000 $ 0
223 2720 00 X XX 000 $ 0
224 4863 O PL 209 0
225 4577 00 X XX 000 $ 0
226 4453 00 X XX 000 $ 0
227 2984 00 X XX 000 $ 0
228 2539 O PL 209 0
229 4600 00 X XX 000 $ 0
230 3661 00 X XX 000 $ 0
231 4608 00 X XX 000 $ 0
232 4740 00 X XX 000 $ 0
233 2796 00 X XX 000 $ 0
234 4606 00 X XX 000 $ 0
235 3135 00 X XX 000 $ 0
236 4833 00 O PL 211 0
237 4561 00 X XX 000 $ 0
238 3823 00 X XX 000 $ 0
239 2645 00 X XX 000 $ 0
240 2787 00 X XX 000 $ 0
241 3108 00 X XX 000 $ 0
242 3226 00 X XX 000 $ 0
243 4516 00 X XX 000 $ 0
----------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
------------------------------------------------------------------------------------------------------------------------------------
TAX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP VS L
------------------------------------------------------------------------------------------------------------------------------------
244 3336 00 X XX 000 $ [***] [***] 0
245 2876 00 X XX 000 $ 0
246 1569 00 X XX 000 $ 0
247 4520 00 X XX 000 $ 0
248 4816 99 O PL 211 0
249 4752 00 X XX 000 0
000 0000 00 X XX 401 $ 0
251 2750 00 X XX 000 $ 0
252 1269 00 X XX 000 $ 0
253 3811 00 X XX 000 $ 0
254 3723 00 X XX 000 $ 0
255 3421 00 X XX 000 $ 0
256 4394 00 X XX 000 $ 0
257 3712 00 X XX 000 $ 0
258 3522 00 X XX 000 $ 0
259 3914 00 X XX 000 $ 0
260 3445 00 X XX 000 $ 0
261 4635 00 X XX 000 $ 0
262 3485 00 X XX 000 $ 0
263 4723 00 X XX 000 $ 0
264 3824 00 X XX 000 $ 0
265 4071 00 X XX 000 $ 0
266 1408 00 X XX 000 $ 0
267 4337 00 X XX 000 $ 0
268 3895 00 X XX 000 $ 0
269 4124 00 X XX 000 $ 0
270 4788 00 O PL 401 0
271 3593 00 X XX 000 $ 0
272 3486 00 X XX 000 $ 0
273 3578 00 X XX 000 $ 0
274 4484 00 X XX 000 $ 0
275 4078 00 X XX 000 $ 0
276 2959 00 X XX 000 $ 0
277 3801 00 X XX 000 $ 0
278 4070 00 X XX 000 $ 0
279 1486 00 X XX 000 $ 0
280 4848 OO O PL 401 0
281 3794 00 X XX 000 $ 0
282 3598 00 X XX 000 $ 0
283 3827 00 X XX 000 $ 0
284 3563 00 X XX 000 $ 0
----------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
-----------------------------------------------------------------------------------------------------------------------------------
TNX CUST SUM OF O
# CUST ID YR TYPE SPECIALTY TER TNXAMT NAME ADDRESS CITY STATE ZIP VS L
-----------------------------------------------------------------------------------------------------------------------------------
285 3528 00 X XX 000 $ [***] O
286 3764 99 O PL 401 $ O
287 3417 99 O PL 401 $ O
288 3589 99 O PL 401 $ O
289 3642 99 O PL 401 $ O
290 3626 99 O PL 401 $ O
291 4750 00 O PL 404 $ O
292 2831 99 O PL 404 $ O
293 1405 99 O PL 404 $ O
294 4099 99 O PL 404 $ O
295 4496 99 O PL 404 $ O
296 2811 99 O PL 404 $ O
297 3883 99 O PL 404 $ O
298 4839 00 O PL 404 $ O
299 4430 99 O PL 404 $ O
300 1283 99 O PL 404 $ O
301 2783 99 O PL 404 $ O
302 2582 99 O PL 404 $ O
303 4616 99 O PL 404 $ O
304 4536 99 O PL 404 $ O
305 4201 99 O PL 404 $ O
306 4832 00 O PL 404 $ O
307 3724 99 O PL 404 $ O
308 2801 99 O PL 404 $ O
309 2601 99 O PL 404 $ O
310 2589 99 O PL 404 $ O
311 2568 99 O PL 404 $ O
312 3809 99 O PL 404 $ O
313 2559 99 O PL 404 $ O
314 3872 99 O PL 404 $ O
315 4745 00 O PL 405 $ O
316 4444 99 O PL 405 $ O
317 3704 99 O PL 405 $ O
318 4769 00 O PL 405 $ O
319 4730 99 O PL 405 $ O
320 4502 99 O PL 405 $ O
321 3345 99 O PL 405 $ O
322 4834 00 O PL 405 $ O
323 4807 00 O PL 405 $ O
324 4388 99 O PL 405 $ O
325 4541 99 O PL 405 $ O
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
-----------------------------------------------------------------------------------------------------------------------------------
TNX CUST SUM OF O
# CUST ID YR TYPE SPECIALTY TER TNXAMT NAME ADDRESS CITY STATE ZIP VS L
-----------------------------------------------------------------------------------------------------------------------------------
326 4550 00 X XX 000 $ [***] O
327 4818 00 O PL 405 $ O
328 3879 99 O PL 405 $ O
329 3356 99 O PL 405 $ O
330 3963 99 O PL 405 $ O
331 4406 99 O PL 406 $ O
332 3825 99 O PL 406 $ O
333 3313 99 O PL 406 $ O
334 4465 99 O PL 406 $ O
335 4703 99 O PL 406 $ O
336 4087 99 O PL 406 $ O
337 3985 99 O PL 406 $ O
338 3812 99 O PL 406 $ O
339 4341 99 O PL 406 $ O
340 4757 00 O PL 406 $ O
341 4098 99 O PL 406 $ O
342 4611 99 O PL 406 $ O
343 4338 99 O PL 406 $ O
344 4307 99 O PL 406 $ O
345 4178 99 O PL 406 $ O
346 4348 99 O PL 406 $ O
347 3694 99 O PL 406 $ O
348 3395 99 O PL 406 $ O
349 4134 99 O PL 406 $ O
350 3291 99 O PL 406 $ O
351 4800 00 O PL 406 $ O
352 3991 99 O PL 406 $ O
353 4231 99 O PL 406 $ O
354 3565 99 O PL 406 $ O
355 4443 99 O PL 406 $ O
356 3962 99 O PL 406 $ O
357 3679 99 O PL 407 $ O
358 3904 99 O PL 407 $ O
359 3096 99 O PL 407 $ O
360 4771 00 O PL 407 $ O
361 3810 99 O PL 407 $ O
362 4852 00 O PL 407 $ O
363 3203 99 O PL 407 $ O
364 4513 99 O PL 407 $ O
365 2436 99 O PL 407 $ O
366 4199 99 O PL 407 $ O
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
# CUST TAX CUST SUM OF O
ID YR TYPE OECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP VS L
============================================================================================================================
367 2953 00 0 XX 000 $ [***] 0
368 2449 00 0 XX 000 $ 0
369 4210 00 0 XX 000 $ 0
370 4015 00 0 XX 000 $ 0
371 4584 00 0 XX 000 $ 0
372 1487 00 0 XX 000 $ 0
373 4088 00 0 XX 000 $ 0
374 3719 00 0 XX 000 $ 0
375 3680 00 0 XX 000 $ 0
376 3439 00 0 XX 000 $ 0
377 4566 00 0 XX 000 $ 0
378 4813 00 0 XX 000 $ 0
379 4382 00 0 XX 000 $ 0
380 3139 00 0 XX 000 $ 0
381 3574 00 0 XX 000 $ 0
382 3454 00 0 XX 000 $ 0
383 4085 00 0 XX 000 $ 0
384 4340 00 0 XX 000 $ 0
385 4447 00 0 XX 000 $ 0
386 1454 00 0 XX 000 $ 0
387 4136 00 0 XX 000 $ 0
388 3778 00 0 XX 000 $ 0
389 4826 00 0 XX 000 $ 0
390 4747 00 0 XX 000 $ 0
391 4706 00 0 XX 000 $ 0
392 3065 00 0 XX 000 $ 0
393 4822 00 0 XX 000 $ 0
394 3684 00 0 XX 000 $ 0
395 4278 00 0 XX 000 $ 0
396 4128 00 0 XX 000 $ 0
397 3529 00 0 XX 000 $ 0
398 3725 00 0 XX 000 $ 0
399 4295 00 0 XX 000 $ 0
400 4409 00 0 XX 000 $ 0
401 3618 00 0 XX 000 $ 0
402 3983 00 0 XX 000 $ 0
403 4540 00 0 XX 000 $ 0
404 1501 00 0 XX 000 $ 0
405 3926 00 0 XX 000 $ 0
406 4411 00 0 XX 000 $ 0
407 4180 00 0 XX 000 $ 0
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
408 3695 00 0 XX 000 $ [***] 0
409 3408 00 0 XX 000 $ 0
410 3948 00 0 XX 000 $ 0
411 1618 00 0 XX 000 $ 0
412 2569 00 0 XX 000 $ 0
413 2858 00 0 XX 000 $ 0
414 2565 00 0 XX 000 $ 0
415 1742 00 0 XX 000 $ 0
416 2967 00 0 XX 000 $ 0
417 4410 00 0 XX 000 $ 0
418 3700 00 0 XX 000 $ 0
419 1677 00 0 XX 000 $ 0
420 3201 00 0 XX 000 $ 0
421 4727 00 0 XX 000 $ 0
422 1635 00 0 XX 000 $ 0
----------------------------------------------------------------------------------------------------------------------------
$
----------------------------------------------------------------------------------------------------------------------------
TOTAL ACCOUNTS FOR OBAGI =
============================================================================================================================
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL LIFECELL CUSTOMER LIST 2/9/2000
EXHIBIT D
-----------------------------------------------------------------------------------------------------------------------------------
TAX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L
------------------------------------------------------------------------------------------------------------------------------------
1 3240 00 X XX 000 $ [***] [***] 9 L
2 3344 99 O PL 101 $ 8 L
3 1332 99 O PL 101 $ 12 L
4 4176 99 O PL 101 $ 5 L
5 3025 99 O PL 101 $ 7 L
6 3834 99 O PL 101 $ 2 L
7 4169 99 O PL 101 $ 1 L
8 3551 99 O PL 101 $ 7 L
9 4221 99 O PL 101 $ 2 L
10 4369 99 O PL 101 $ 1 L
11 3189 99 O PL 101 $ 2 L
12 3726 99 O PL 101 $ 3 L
13 4712 99 O PL 101 $ 2 L
14 4147 99 O PL 101 $ 3 L
15 1565 99 O PL 102 $ 3 L
16 3131 99 O PL 102 $ 8 L
17 3090 99 O PL 102 $ 4 L
18 3016 99 O PL 102 $ 7 L
19 3204 99 O PL 102 $ 7 L
20 3492 99 O PL 102 $ 3 L
21 3138 99 O PL 102 $ 3 L
22 4184 99 O PL 102 $ 1 L
23 4287 99 O PL 102 $ 2 L
24 3057 99 O PL 102 $ 2 L
25 3627 99 O PL 102 $ 2 L
26 1352 99 O PL 102 $ 1 L
27 3754 99 O PL 102 $ 1 L
28 4153 99 O PL 102 $ 1 L
29 4507 99 O PL 102 $ 1 L
30 4515 99 O PL 102 $ 1 L
31 3051 99 O DM 103 $ 6 L
32 4066 99 O PL 103 $ 5 L
33 3202 99 O PL 103 $ 8 L
34 4630 99 O PL 103 $ 1 L
35 4633 99 O PL 103 $ 1 L
36 2518 99 O PL 103 $ 9 L
37 3230 99 O PL 103 $ 3 L
38 4407 99 O PL 103 $ 2 L
39 3401 99 O PL 103 $ 4 L
40 3716 99 O PL 103 $ 3 L
41 2530 99 O PL 103 $ 4 L
42 3857 99 O PL 103 $ 3 L
43 3631 99 O PL 103 $ 1 L
44 4040 99 O PL 103 $ 1 L
45 3212 99 O PL 103 $ 1 L
46 4343 99 O PL 103 $ 1 L
47 3199 99 O PL 103 $ 3 L
48 3427 99 O PL 103 $ 1 X
00 0000 00 X XX 103 $ X
00 0000 00 X XX 104 $ 00 X
00 0000 00 X XX 104 $ 00 X
00 0000 00 X XX 104 $ 4 L
53 3403 99 O PL 104 $ 2 L
54 3535 99 O PL 104 $ 1 L
55 4427 99 O PL 104 $ 3 L
56 4122 99 O PL 104 $ 1 L
57 4495 99 O PL 104 $ 2 L
58 4518 99 O PL 104 $ 1 L
59 4732 99 O PL 104 $ 1 L
60 4275 99 O PL 104 $ 5 L
61 4125 99 O PL 104 $ 2 L
62 3003 99 O PL 104 $ 3 L
63 2487 99 O PL 104 $ 1 L
64 3630 99 O PL 104 $ 1 L
65 1375 99 O PL 105 $ 7 L
66 3066 99 O PL 105 $ 00 X
00 0000 00 X XX 105 $ 8 L
68 3180 99 O PL 105 $ 7 L
69 1393 99 O PL 105 $ 4 L
70 3020 99 O PL 105 $ 4 L
71 3120 99 O PL 105 $ 6 L
72 2974 99 O PL 105 $ 8 L
73 3352 99 O PL 105 $ 8 L
74 3088 99 O PL 105 $ 8 L
75 3497 99 O PL 105 $ 6 L
76 2907 99 O PL 105 $ 7 L
77 2935 99 O PL 105 $ 2 L
78 4288 99 O PL 105 $ 2 L
79 3653 99 O PL 105 $ 4 L
80 3936 99 O PL 105 $ 3 L
81 3229 99 O PL 105 $ 3 L
82 2918 99 O PL 105 $ 7 L
83 3102 99 O PL 105 $ 3 L
84 4401 99 O PL 105 $ 2 L
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL LIFECELL CUSTOMER LIST 2/9/2000 EXHIBIT D
-----------------------------------------------------------------------------------------------------------------------------------
TAX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L
------------------------------------------------------------------------------------------------------------------------------------
85 4273 99 O PL 105 $ [***] 3 L
86 3970 99 O PL 105 $ 1 X
00 0000 00 X XX 105 L
88 9999 00 X XX 000 X
00 0000 00 X XX 106 L
90 4874 00 X XX 000 X
00 0000 00 X XX 106 L
92 4876 00 X XX 000 X
00 0000 00 X XX 106 L
94 4878 00 X XX 000 X
00 0000 00 X XX 106 L
96 4880 00 X XX 000 X
00 0000 00 X XX 106 L
98 4883 00 X XX 000 X
00 0000 00 X XX 106 L
100 4885 00 X XX 000 X
000 0000 00 X XX 106 L
102 4888 00 X XX 000 X
000 0000 00 X XX 107 $ 6 L
104 3663 99 O PL 107 $ 3 L
105 3155 99 O PL 107 $ 3 L
106 3951 99 O PL 107 $ 7 L
107 4497 99 O PL 107 $ 3 L
108 3566 99 O PL 107 $ 6 L
109 4274 99 O PL 107 $ 4 L
110 3892 99 O PL 107 $ 6 L
111 3127 99 O PL 107 $ 3 L
112 4300 99 O PL 107 $ 3 L
113 4602 99 O PL 107 $ 2 L
114 4258 99 O PL 107 $ 1 L
115 2606 99 O PL 107 $ 3 L
116 2604 99 O PL 107 $ 2 L
117 4437 99 O PL 107 $ 1 L
118 3740 99 O PL 107 $ 2 L
119 3906 99 O PL 107 $ 1 L
120 4619 99 O PL 107 $ 1 L
121 2611 99 O PL 107 $ 1 L
122 4266 99 O PL 107 $ 2 L
123 3038 99 O DM 108 $ 10 L
124 3330 99 O PL 108 $ 18 L
125 2609 99 O PL 108 $ 4 L
126 2602 99 O PL 108 $ 6 L
----------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
-----------------------------------------------------------------------------------------------------------------------------------
TAX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L
------------------------------------------------------------------------------------------------------------------------------------
127 3727 00 X XX 000 $ [***] 9 L
128 4001 99 O PL 108 $ 6 L
129 3079 99 O PL 108 $ 9 L
130 2893 99 O PL 108 $ 7 L
131 3130 99 O PL 108 $ 00 X
000 0000 00 X XX 108 $ 21 L
133 2979 99 O DM 108 $ 4 L
134 3217 99 O DM 108 $ 3 L
135 2982 99 O PL 108 $ 6 L
136 3106 99 O PL 108 $ 5 L
137 1374 99 O PL 108 $ 1 L
138 4628 00 O PL 106 $ 1 L
139 3606 99 O PL 108 $ 13 L
140 2901 99 O PL 108 $ 4 L
141 2622 99 O PL 108 $ 4 L
142 3366 99 O PL 108 $ 10 L
143 3560 99 O PL 108 $ 5 L
144 3125 99 O PL 108 $ 7 L
145 4554 99 O PL 108 $ 2 L
146 3235 99 O PL 108 $ 2 L
147 3484 99 O PL 109 $ 00 X
000 0000 00 X XX 109 $ 13 L
149 3333 99 O PL 109 $ 7 L
150 3634 99 O PL 109 $ 6 L
151 3646 99 O PL 109 $ 3 L
152 3112 99 O PL 109 $ 1 L
153 3833 99 O PL 109 $ 4 L
154 4016 99 O PL 109 $ 2 L
155 3935 99 O PL 109 $ 3 L
156 3238 99 O PL 109 $ 4 L
157 3210 99 O PL 109 $ 4 L
158 3039 99 O PL 109 $ 5 L
159 3222 99 O PL 109 $ 2 L
160 3188 99 O PL 109 $ 4 L
161 4247 99 O PL 109 $ 1 L
162 2053 99 O PL 109 $ 2 L
163 3603 99 O PL 202 $ 3 L
164 3328 99 O PL 202 $ 6 L
165 3380 99 O PL 202 $ 5 L
166 3511 99 O PL 202 $ 4 L
167 3404 99 O PL 202 $ 9 L
168 3796 99 O PL 202 $ 2 L
-----------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL LIFECELL CUSTOMER LIST 2/9/2000 EXHIBIT D
-----------------------------------------------------------------------------------------------------------------------------------
TAX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L
------------------------------------------------------------------------------------------------------------------------------------
169 4063 00 X XX 000 $ [***] [***] 2 L
170 4200 99 O PL 202 $ 2 L
171 4357 99 O PL 202 $ 2 L
172 3696 99 O PL 202 $ 4 L
173 3613 99 O PL 202 $ 4 L
174 3388 99 O PL 202 $ 2 L
175 3981 99 O PL 202 $ 1 L
176 4364 99 O PL 202 $ 1 L
177 4223 99 O PL 202 $ 2 L
178 4460 99 O PL 202 $ 1 L
179 3436 99 O PL 204 $ 15 L
180 3881 99 O PL 204 $ 9 L
181 3350 99 O PL 204 $ 12 L
182 3514 99 O PL 204 $ 6 L
183 3671 99 O PL 204 $ 6 L
184 3570 99 O PL 204 $ 10 L
185 3739 99 O PL 204 $ 6 L
186 3707 99 O PL 204 $ 4 L
187 3874 99 O PL 204 $ 4 L
188 4454 99 O PL 204 $ 3 L
189 3807 99 O PL 204 $ 2 L
190 3469 99 O PL 204 $ 4 L
191 3850 99 O PL 204 $ 1 L
192 4089 99 O PL 204 $ 2 L
193 4091 99 O PL 204 $ 2 L
194 3326 99 O PL 204 $ 3 L
195 3406 99 O PL 204 $ 3 L
196 3910 99 O PL 204 $ 4 L
197 3458 99 O PL 204 $ 3 L
198 3331 99 O PL 204 $ 2 L
199 3451 99 O PL 206 $ 00 X
000 0000 00 X XX 206 $ 10 L
201 3548 99 O PL 206 $ 4 L
202 3715 99 O PL 206 $ 6 L
203 4116 99 O PL 206 $ 5 L
204 3068 99 O PL 206 $ 5 L
205 3493 99 O PL 206 $ 5 L
206 4377 99 O PL 206 $ 2 L
207 4504 99 O PL 206 $ 2 L
208 3190 99 O PL 206 $ 4 L
209 3273 99 O PL 206 $ 4 L
210 1654 99 O PL 208 $ 4 L
------------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL LIFECELL CUSTOMER LIST 2/9/2000 EXHIBIT D
-----------------------------------------------------------------------------------------------------------------------------------
TAX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L
------------------------------------------------------------------------------------------------------------------------------------
211 3341 00 X XX 000 $ [***] [***] 2 L
212 3547 99 O PL 206 $ 1 L
213 3645 99 O PL 206 $ 2 L
214 4825 00 X XX 000 X
000 0000 00 X XX 206 L
216 1543 99 O PL 207 $ 00 X
000 0000 00 X XX 207 $ 28 L
218 3158 99 O PL 207 $ 7 L
219 1604 99 O PL 207 $ 7 L
220 2467 99 O PL 207 $ 16 L
221 2870 99 O PL 207 $ 9 L
222 1462 99 O PL 207 $ 5 L
223 1571 99 O PL 207 $ 4 L
224 3096 99 O PL 207 $ 6 L
225 2922 99 O PL 207 $ 3 L
226 2753 99 O PL 207 $ 2 L
227 2411 99 O PL 207 $ 4 L
228 2985 99 O PL 207 $ 3 L
229 1589 99 O PL 207 $ 3 L
230 3205 99 O PL 207 $ 2 L
231 1337 99 O PL 207 $ 11 L
232 2590 99 O PL 207 $ 2 L
233 3544 99 O PL 207 $ 3 L
234 3545 99 O PL 207 $ 1 L
235 1557 99 O PL 207 $ 1 L
236 2456 99 O PL 208 $ 9 L
237 2470 99 O PL 208 $ 14 L
238 2324 99 O PL 208 $ 5 L
239 1743 99 O PL 208 $ 7 L
240 4627 99 O PL 208 $ 1 L
241 4634 99 O PL 208 $ 1 L
242 2423 99 O PL 208 $ 2 L
243 2763 99 O PL 208 $ 5 L
244 1636 99 O PL 208 $ 5 L
245 3795 99 O PL 208 $ 1 L
246 2401 99 O PL 208 $ 2 L
247 2885 99 O PL 208 $ 5 L
248 4162 99 O PL 208 $ 1 L
249 3937 99 O PL 208 $ 2 L
250 2618 99 O PL 208 $ 1 L
251 2595 99 O PL 208 $ 1 L
252 3588 99 O PL 208 $ 1 L
------------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL LIFECELL CUSTOMER LIST 2/9/2000 EXHIBIT D
-----------------------------------------------------------------------------------------------------------------------------------
CUST TNX CUST SPECI- SUM OF O
# ID YR TYPE ALTY TER TNXAMT NAME ADDRESS CITY STATE ZIP # VS L
-----------------------------------------------------------------------------------------------------------------------------------
253 4860 O PL 208 [***] X
000 0000 X XX 208 L
255 0000 X XX 000 X
000 0000 X XX 208 L
257 2735 99 O PL 209 $ 00 X
000 0000 00 X XX 209 $ 00 X
000 0000 00 X XX 209 $ 00 X
000 0000 00 X XX 209 $ 15 L
261 1457 99 O PL 209 $ 5 L
262 2858 99 O PL 209 $ 6 L
263 2553 99 O PL 209 $ 8 L
264 2589 99 O PL 209 $ 5 L
265 2453 99 O PL 209 $ 4 L
266 3513 99 O PL 209 $ 9 L
267 2893 99 O PL 209 $ 5 L
268 2550 99 O PL 209 $ 4 L
269 3054 99 O PL 209 $ 3 L
270 1148 99 O PL 209 $ 3 L
271 2440 99 O PL 209 $ 1 L
272 4434 99 O PL 209 $ 2 L
273 4009 99 O PL 209 $ 2 L
274 4547 99 O PL 209 $ 1 L
275 4746 O PL 209 L
276 2572 99 O PL 210 $ 14 L
277 2473 99 O PL 210 $ 9 L
278 2649 99 O PL 210 $ 5 L
279 3743 99 O PL 210 $ 1 L
280 1504 99 O PL 210 $ 5 L
281 4404 99 O PL 210 $ 3 L
282 4374 99 O PL 210 $ 1 L
283 4483 99 O PL 210 $ 1 L
284 4304 99 O PL 210 $ 1 X
000 0000 X XX 210 L
286 0000 X XX 000 X
000 0000 X XX 210 L
288 1534 99 O PL 211 $ 17 L
289 2746 99 O PL 211 $ 8 L
290 2764 99 O PL 211 $ 11 L
291 3167 99 O PL 211 $ 5 L
292 2947 99 O PL 211 $ 4 L
293 4218 99 O PL 211 $ 1 L
294 2917 99 O PL 211 $
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
FINAL LIFECELL CUSTOMER LIST 2/9/2000 EXHIBIT D
-----------------------------------------------------------------------------------------------------------------------------------
CUST TNX CUST SPECI- SUM OF O
# ID YR TYPE ALTY TER TNXAMT NAME ADDRESS CITY STATE ZIP # VS L
-----------------------------------------------------------------------------------------------------------------------------------
295 2639 00 X XX 000 $ [***] 3 L
296 2631 99 O PL 211 $ 2 L
297 2892 99 O PL 211 $ 2 L
298 4322 99 O PL 211 $ 1 L
299 2879 99 O PL 211 $ 1 L
300 2903 99 O PL 211 $ 2 L
301 2899 99 O PL 211 $ 2 L
302 3621 99 O PL 401 $ 00 X
000 0000 00 X XX 401 $ 23 L
304 3348 99 O PL 401 $ 5 L
305 3546 99 O PL 401 $ 5 L
306 3457 99 O PL 401 $ 00 X
000 0000 00 X XX 401 $ 16 L
308 1396 99 O PL 401 $ 2 L
309 3324 99 O PL 401 $ 00 X
000 0000 00 X XX 401 $ 14 L
311 3353 99 O PL 401 $ 5 L
312 3777 99 O PL 401 $ 4 L
313 4129 99 O PL 401 $ 5 L
314 1614 99 O PL 401 $ 7 L
315 4135 99 O PL 401 $ 2 L
316 3822 99 O PL 401 $ 3 L
317 3944 99 O PL 401 $ 3 L
318 2734 99 O PL 401 $ 4 L
319 3688 99 O PL 401 $ 2 L
320 4356 99 O PL 401 $ 2 L
321 2540 99 O PL 404 $ 00 X
000 0000 00 X XX 404 $ 13 L
323 1482 99 O PL 404 $ 8 L
324 3880 99 O PL 404 $ 5 L
325 2797 99 O PL 404 $ 7 L
326 2762 99 O PL 404 $ 4 L
327 4029 99 O PL 404 $ 2 L
328 2576 99 O PL 404 $ 6 L
329 2789 99 O PL 404 $ 3 L
330 3162 99 O PL 404 $ 3 L
331 2632 99 O PL 404 $ 3 L
332 2956 99 O PL 404 $ 2 L
333 2963 99 O PL 404 $ 3 L
334 3693 99 O PL 404 $ 3 L
335 3873 99 O PL 404 $ 5 L
336 2197 99 O PL 405 $ 7 L
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
Final LifeCell Customer List 2/9/2000 EXHIBIT D
-----------------------------------------------------------------------------------------------------------------------------------
TAX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L
------------------------------------------------------------------------------------------------------------------------------------
337 3475 99 O PL 405 [***] [***] 9 X
000 0000 00 X XX 405 4 L
339 3523 00 X XX 000 0 X
000 0000 00 X XX 405 4 L
341 3520 00 X XX 000 0 X
000 0000 00 X XX 405 4 L
343 3315 00 X XX 000 0 X
000 0000 00 X XX 405 3 X
000 0000 00 X XX 405 3 L
346 3420 00 X XX 000 0 X
000 0000 00 X XX 405 2 L
348 3718 00 X XX 000 0 X
000 0000 00 X XX 405 2 L
350 3913 00 X XX 000 0 X
000 0000 00 X XX 405 2 L
352 4735 00 X XX 000 0 X
000 0000 00 X XX 405 2 L
354 3274 00 X XX 000 0 X
000 0000 00 X XX 000 00 X
000 3246 00 X XX 000 0 X
000 0000 00 X XX 406 7 L
358 3293 00 X XX 000 0 X
000 0000 00 X XX 000 00 X
000 3294 00 X XX 000 0 X
000 0000 00 X XX 406 2 L
362 3281 00 X XX 000 0 X
000 0000 00 X XX 406 1 L
364 3266 00 X XX 000 0 X
000 0000 00 X XX 406 3 L
366 3278 00 X XX 000 0 X
000 0000 00 X XX 406 5 L
368 3300 00 X XX 000 0 X
000 0000 00 X XX 406 1 X
000 0000 00 X XX 406 3 L
371 4522 99 O PL 406 3 X
000 0000 00 X XX 406 2 L
373 3253 00 X XX 000 0 X
000 0000 00 X XX 406 3 L
375 3683 00 X XX 000 0 X
000 0000 00 X XX 000 00 X
000 3007 00 X XX 000 0 X
000 0000 00 X XX 407 10 L
------------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
-----------------------------------------------------------------------------------------------------------------------------------
TAX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L
------------------------------------------------------------------------------------------------------------------------------------
379 3814 99 O PL 407 [***] [***] 9 X
000 0000 00 X XX 000 00 X
000 3393 00 X XX 000 0 X
000 0000 00 X XX 407 3 L
383 2404 00 X XX 000 0 X
000 0000 00 X XX 407 3 X
000 0000 00 X XX 407 5 L
386 2981 00 X XX 000 0 X
000 0000 00 X XX 407 2 L
388 2427 00 X XX 000 0 X
000 0000 00 X XX 407 1 L
390 4553 00 X XX 000 0 X
000 0000 00 X XX 000 00 X
000 3393 00 X XX 000 00 X
000 0000 00 X XX 000 00 X
000 3549 00 X XX 000 0 X
000 0000 00 X XX 000 00 X
000 3243 00 X XX 000 0 X
000 0000 00 X XX 408 8 X
000 0000 00 X XX 000 00 X
000 3601 00 X XX 000 0 X
000 0000 00 X XX 408 2 X
000 0000 00 X XX 408 7 L
402 3437 00 X XX 000 0 X
000 0000 00 X XX 408 4 X
000 0000 00 X XX 408 5 L
405 4252 00 X XX 000 0 X
000 0000 00 X XX 408 6 X
000 0000 00 X XX 408 6 L
408 4097 00 X XX 000 0 X
000 0000 00 X XX 408 1 L
410 4657 00 X XX 000 0 X
000 0000 00 X XX 408 L
412 4651 00 X XX 000 X
000 0000 00 X XX 408 L
414 9999 00 X XX 000 X
000 0000 00 X XX 408 L
416 3673 00 X XX 000 0 X
000 0000 00 X XX 409 5 L
418 3620 00 X XX 000 0 X
000 0000 00 X XX 409 9 L
420 3917 99 O PL 409 7 L
------------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
-----------------------------------------------------------------------------------------------------------------------------------
TAX CUST SUM OF O
# CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L
------------------------------------------------------------------------------------------------------------------------------------
421 3558 99 O PL 409 [***] [***] 2 L
422 3826 00 X XX 000 0 X
000 0000 00 X XX 409 4 L
424 3373 00 X XX 000 0 X
000 0000 00 X XX 409 7 L
426 3414 00 X XX 000 0 X
000 0000 00 X XX 409 3 L
428 3786 00 X XX 000 0 X
000 0000 00 X XX 409 1 L
430 3933 00 X XX 000 0 X
000 0000 00 X XX 409 1 L
432 4544 99 O PL 409 2 L
------------------------------------------------------------------------------------------------------------------------------------
Total count for LifeCall List =
[***] Material has been omitted pursuant to a request for confidential
treatment and such material has been filed separately with the
Securities and Exchange Commission.
EXHIBIT E
PRODUCT STORAGE, HANDLING AND TRANSPORTATION SPECIFICATIONS AND PROCEDURES
The following policies and procedures are based on the Standards of the
American Association of Tissue Banks (1996) and specifically address the
issue of "Tissue Distribution Intermediates" (Section M). Technical
assistance is available from LifeCell to facilitate the incorporation of
these procedures.
Appropriate documentation is critical. Particular attention should be paid to
the following areas:
Documentation of receipt of tissue
Lot/graft numbers
Expiration date
Received by
Date of receipt
Condition of packaging
Documentation of storage conditions
Temperature monitoring
Documentation of distribution
Date of order
Consignee name and address
Identification of person placing the order
Type and quantity of tissue ordered
Information regarding tissue shipped
Identification number(s) of tissue(s)
Expiration date of tissue
Date of shipment
Mode of transportation
Name of Individual filling order
Documentation of final package inspection prior to distribution
ADDITIONAL REQUIREMENTS:
STORAGE EQUIPMENT
All storage equipment (i.e., refrigerator(s)) must be regularly maintained (i.e.
preventative maintenance program)), calibrated, and monitored.
Monitoring of refrigerators may consist of the installation of a continuous
temperature recording device or a routine (once each working day) and DOCUMENTED
check of temperature utilizing a refrigerator thermometer. Acceptable
temperature range for the storage of Products is 2 - 8DEG.C. Products may be
stored in a standard household refrigerator provided that this temperature range
can be maintained.
-5-
ADVERSE OUTCOMES
All reports of complaints or adverse outcomes must be required to be forwarded
immediately to LifeCell.
RETURN OF TISSUE
All expired, returned, damaged, or otherwise compromised packages or grafts must
be returned to LifeCell.
TRANSPORTATION
Products may be shipped to customers by commercial overnight courier services
without adherence to any of the product storage and handling policies and
procedures set forth in this EXHIBIT A.
-6-
